Last Updated: 13 November 2026
Elevance Health is one of the largest US health insurers. Its Health Benefits segment runs Anthem Blue Cross and Blue Shield plans in 14 states, Blue Cross plans in California and Wellpoint, Simply and MMM plans across commercial, Medicare and Medicaid markets. Its Carelon businesses sell pharmacy benefit services, behavioural health, home-based care and payment-integrity services to its own members and to outside clients. FY2025 total revenue was $199.1bn, and the company serves about 45 million medical members. This report covers the latest filings, including Q3 2026 results released on 21 Oct 2026. Track the shares on our Live Charts, check market-moving events on the Economic Calendar, and join the discussion in the ChartsView Forum.
1. Company Snapshot
| Field | Value |
|---|---|
| Ticker / Exchange | ELV / NYSE |
| Headquarters | 220 Virginia Avenue, Indianapolis, Indiana |
| Corporate history | Formerly Anthem, Inc.; renamed Elevance Health in 2022 |
| CEO / Leadership | Gail K. Boudreaux, President & CEO; Mark Kaye, EVP & CFO; Jeff Park joins as President of Carelon on 01 Dec 2026 |
| Employees | ~97,100 at 31 Dec 2025 (about 71,900 in the US), per the FY2025 10-K |
| Sector | Healthcare / Managed care |
| Market cap | ~$92.8bn (12 Nov 2026 close of $429.89) |
| FY2025 Revenue | $199,125m total revenue (+12.5% YoY); operating revenue $197,584m |
| FY2025 net income | $5,662m; GAAP diluted EPS $25.21; adjusted EPS $30.29 |
| Medical members | 44.9m at 30 Sep 2026 (45.2m at 31 Dec 2025) |
| Dividend | $1.72 quarterly ($6.88 annualised), up from $1.71 in 2025 |
| Shares outstanding | 216.9m (10 Jul 2026, Q2 2026 10-Q cover) |
| Fiscal year end | 31 December |
2. Bull Case vs Bear Case
Bull Case
- Guidance raised three times: 2026 adjusted EPS guidance has moved from at least $25.50 in January to at least $29.00 on 21 Oct 2026, and operating cash flow guidance from at least $5.5bn to at least $6.5bn.
- 2027 growth target: Management guided to at least 12% adjusted EPS growth in 2027 from a 2026 baseline of at least $26.75, with Medicaid and Medicare Advantage margins expected to improve.
- Carelon momentum: Carelon operating gain rose 17% in Q3 2026 to a 4.7% margin, and management said it has secured a number of new external services contracts for 2027.
- Cash returns: $4.1bn returned in 2025 (including $2.6bn of buybacks), about $5.0bn of buyback authorisation left at 30 Sep 2026, and a dividend raised every year since FY2021.
Bear Case
- Revenue has stalled: Q3 2026 operating revenue grew just 0.7%, and medical membership fell from 45.2m to 44.9m in 2026, with Medicare members down 10.4% year on year.
- Medical costs still elevated: The FY2025 benefit expense ratio rose 150bp to 90.0%, and the Q3 2026 ratio was 90.6%, leaving thin margins in Health Benefits (2.5% operating margin in FY2025).
- Medicare Advantage headwinds: A $935m accrual for a CMS risk-adjustment notice hit Q1 2026, and only about half of Medicare Advantage members are in 4-star or better plans for the 2027 Stars year.
- Policy exposure: Expired ACA premium subsidies, Medicaid eligibility changes and PBM regulation all bear directly on Elevance's three largest markets.
3. Segments & Revenue Mix
FY2025 segment revenue as a share of operating revenue of $197,584m. Shares add to more than 100% because $41,689m of intersegment revenue (mainly Carelon services to Elevance's own health plans) is eliminated on consolidation.
| Segment | % of revenue | What it is |
|---|---|---|
| Health Benefits | 84.6% ($167,094m) | Risk-based and fee-based medical plans across Individual, Employer Group, Medicare, Medicaid and the Federal Employee Program. FY2025 operating gain $4,158m (2.5% margin). |
| CarelonRx | 22.0% ($43,400m) | Pharmacy benefit management, home-delivery and specialty pharmacy and Paragon infusion centres; core PBM services are delegated to CVS Caremark under a contract running to 31 Dec 2027. FY2025 operating gain $2,418m. |
| Carelon Services | 14.3% ($28,316m) | Behavioural health, medical benefits management, CareBridge home and community-based care, palliative care and Carelon Insights payment-integrity services. FY2025 operating gain $960m. |
| Corporate & Other | 0.2% ($463m) | Smaller businesses and unallocated corporate costs. FY2025 operating loss $337m. |
Within Health Benefits, FY2025 revenue split into Medicaid $56,620m, Commercial $50,401m, Medicare $44,752m and the Federal Employee Program $15,321m. At 30 Sep 2026 medical membership was 44.88m: commercial fee-based 27.6m, commercial risk-based 4.7m, Medicaid 8.2m, Medicare Advantage 1.9m, Medicare Supplement 0.9m and FEP 1.5m.
4. Business Model & Moat
How it makes money. In risk-based plans Elevance collects premiums and keeps what is left after paying medical claims and running costs; the benefit expense ratio was 90.0% in FY2025. In fee-based commercial plans, which cover most of its members, employers carry the medical risk and pay administrative fees. Carelon earns fees and margins on pharmacy, specialty care and services sold both inside the group and to outside health plans.
Blue brand and local scale. As an exclusive Blue Cross Blue Shield licensee in its 14 states, Elevance has dense provider networks and strong brand recognition with employers, which makes its commercial position hard to dislodge. Fee-based commercial membership grew to 27.6m at 30 Sep 2026 from 27.1m at the end of 2025.
Integrated services. Carelon lets Elevance keep more of each healthcare dollar within the group, and selling the same services to other insurers gives it a growing fee-based revenue stream less exposed to medical cost swings.
Capital allocation. Elevance bought back $1.7bn of stock in the first nine months of 2026 (5.2m shares), pays a $1.72 quarterly dividend and had about $2.4bn of cash and investments at the parent company at 30 Sep 2026.
5. Financial Health
Annual figures from Elevance's 10-K filings, SEC XBRL data and Q4 earnings releases. Revenue is total revenue including net investment income.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| FY2021 | $138,639m | +13.8% | $24.95† | $25.98† | $4.52 | $21,157m |
| FY2022 | $156,595m | +13.0% | $24.28† | $28.53† | $5.12 | $22,349m |
| FY2023 | $171,340m | +9.4% | $25.22 | $33.14 | $5.92 | $23,246m |
| FY2024 | $177,011m | +3.3% | $25.68 | $33.04 | $6.52 | $29,218m |
| FY2025 | $199,125m | +12.5% | $25.21 | $30.29 | $6.84 | $30,797m |
† FY2021 and FY2022 GAAP EPS are shown as recast for the 2023 insurance accounting change (LDTI); FY2022 adjusted EPS is the recast $28.53 ($29.07 as first reported). FY2021 adjusted EPS is as first reported. Long-term debt excludes the current portion ($1,099m at end-2025). FY2021 growth is measured against FY2020 total revenue of $121,867m.
Quarterly results, most recent first. Revenue is total revenue.
| Quarter / Half | Revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q3 2026 | $51,429m (+1.4%) | $6.99 | $6.27 |
| Q2 2026 | $50,474m (+1.4%) | $7.45 | $6.71 |
| Q1 2026 | $50,181m (+2.6%) | $12.58 | $8.00 |
| Q4 2025 | $49,747m | $3.33 | $2.47 |
| Q3 2025 | $50,711m | $6.03 | $5.32 |
| Q2 2025 | $49,776m | $8.84 | $7.72 |
| Q1 2025 | $48,891m | $11.97 | $9.61 |
| 9M 2026 total | $152,084m | $27.06 | $21.01 |
| FY2025 total | $199,125m | $30.29 | $25.21 |
Q1 2026 GAAP EPS includes a $935m ($4.24 per share) accrual for a 27 Feb 2026 CMS notice on historical Medicare Advantage risk-adjustment data; Q1 2026 adjusted EPS includes about $1 per share of non-recurring investment income. Q4 2025 revenue is derived as FY2025 less the nine-month total. Benefit expense ratio: 90.6% in Q3 2026 (91.3% in Q3 2025).
Cash flow and balance sheet. FY2025 operating cash flow was $4,290m, capex (purchases of property and equipment) $1,116m, and depreciation and amortisation $1,546m. Nine-month 2026 operating cash flow was much stronger at $7,512m, with capex of $789m and D&A of $1,083m; full-year guidance is at least $6.5bn. At 30 Sep 2026 total debt was $30,757m ($30,382m long-term plus a $375m current portion, with no short-term borrowings), against cash and cash equivalents of $10,348m and a $25,347m fixed-maturity securities portfolio that largely backs insurance liabilities. Shareholders' equity was $44,681m.
6. Valuation Snapshot
Raw metrics, November 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Share price | $429.89 (12 Nov 2026 close) |
| Market cap | ~$92.8bn (12 Nov 2026) |
| 52-week high | $450.69 (as of 12 Nov 2026) |
| 52-week low | $274.84 (as of 12 Nov 2026) |
| Trailing P/E (GAAP) | ~18.3x (TTM GAAP EPS $23.55 = FY2025 $25.21 - 9M 2025 $22.67 + 9M 2026 $21.01). On TTM adjusted EPS of $30.47 the multiple is ~14.1x. |
| P/E (forward) | ~14.8x on company 2026 adjusted EPS guidance of at least $29.00 |
| P/S (TTM) | ~0.46x (market cap ~$92.8bn / TTM total revenue $201,831m) |
| P/FCF | ~14.2x (market cap ~$92.8bn / TTM FCF ~$6,514m; FCF = operating CF $7,596m - capex $1,082m, TTM to Q3 2026). On FY2025 FCF of $3,174m ($4,290m - $1,116m) the multiple is ~29x. |
| Enterprise value | ~$113.2bn (market cap ~$92.8bn + total debt $30,757m - cash $10,348m per 30 Sep 2026 balance sheet; the $25.3bn fixed-maturity portfolio is excluded as it backs insurance reserves) |
| EV/EBITDA (TTM) | ~16.4x (EV ~$113.2bn / TTM EBITDA ~$6,916m; operating income $5,427m + D&A $1,489m, TTM to Q3 2026). TTM operating income is reduced by the $935m Q1 2026 CMS accrual; excluding it the multiple is ~14.4x. |
| Price/book | ~2.1x (market cap ~$92.8bn / shareholders' equity $44,681m at 30 Sep 2026) |
| Dividend yield | ~1.6% ($6.88 annualised / $429.89) |
| Short interest (% of float) | ~2.1% of shares outstanding (4.54m shares short, 30 Oct 2026 FINRA settlement via Equibles); MarketBeat showed 2.54% of float at 31 Aug 2026 |
| Days to cover | 3.26 (30 Oct 2026 settlement) |
7. What Are They Building
- Carelon growth: Carelon Services' risk-based solutions grew revenue 8.2% in the first nine months of 2026, and new external services contracts have been secured for 2027. Jeff Park, former president of Waltz Health and COO of Optum Rx, takes over as Carelon president on 01 Dec 2026.
- Specialty pharmacy and infusion: CarelonRx is expanding specialty pharmacy and home and alternate-site infusion through Paragon Healthcare, acquired in 2024.
- Home-based care: CareBridge, acquired at the end of 2024, provides home and community-based services for Medicaid and dual-eligible members with complex needs.
- AI and data: Management described AI-enabled workflows in risk-adjustment programmes and AI analytics to detect inappropriate billing, alongside the HealthOS clinical data exchange that links providers and payers.
- Targeted investments: One-time spending in 2026 on medical cost management, provider connectivity and efficiency lifted the adjusted operating expense ratio by 90bp in Q3 2026.
- Mosaic Health: A primary-care joint venture with Clayton, Dubilier & Rice.
8. Competitive Landscape
| Peer | Market cap (November 2026) | Key 2025 metric |
|---|---|---|
| UnitedHealth Group (UNH) | ~$363.0bn (12 Nov 2026, Equibles) | FY2025 revenue $447.6bn |
| CVS Health (CVS) | ~$114.9bn (12 Nov 2026, Equibles) | FY2025 revenue $402.1bn |
| The Cigna Group (CI) | ~$79.4bn (11 Nov 2026, Equibles) | FY2025 revenue $274.9bn (+11%) |
| Humana (HUM) | ~$52.1bn (09 Nov 2026, Trefis) | FY2025 revenue $129.7bn |
| Centene (CNC) | ~$34.5bn (06 Nov 2026, Equibles) | FY2025 revenue $194.8bn |
Elevance competes with UnitedHealthcare, Aetna (CVS), Cigna and Humana for employer and Medicare business, and with Centene and Molina in Medicaid. CarelonRx competes with the three largest PBMs: Optum Rx, CVS Caremark and Express Scripts.
9. Insider Activity
CEO Gail Boudreaux bought about $1.0m of stock in the open market in July 2026, the largest insider purchase of the year. Since the Q3 2026 results, CFO Mark Kaye and Chief Digital Officer Ratnakar Lavu have sold shares. Annual stock awards and tax withholding are excluded.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Ratnakar Lavu (EVP, Chief Digital & Information Officer) | 05 Nov 2026 | Sale | 1,300 | $440.00 | ~$0.57m | Not stated on Form 4 |
| Mark Kaye (EVP & CFO) | 22 Oct 2026 | Sale (13 lots) | 10,584 | ~$440.13 (wtd avg) | ~$4.66m | Not stated on Form 4 |
| Gail K. Boudreaux (President & CEO) | Jul 2026 | Purchase | 2,725 | $367.79 | ~$1.00m | Open market |
| Ramiro Peru (Director) | Jul 2026 | Purchase | 1,000 | $366.05 | ~$0.37m | Open market |
| Robert Dixon Jr (Director) | 11 Jun 2026 | Sale | 151 | $401.77 | ~$0.06m | Not stated |
| Morgan Kendrick (EVP) | 06 Mar 2026 | Sale | 3,196 | $284.92 | ~$0.91m | Not stated |
| Steven Collis (Director) | Mar 2026 | Purchase | 3,000 | $289.84 | ~$0.87m | Open market |
Source: SEC Form 4 filings for CIK 1156039 and insider-tracking summaries. July and March dates are approximate to the month.
10. Key Risks
- Medical cost trend: Elevated utilisation in ACA, Medicaid and Medicare pushed the benefit expense ratio to 90.0% in FY2025; a further rise would erode already thin Health Benefits margins.
- Medicaid funding and eligibility: Higher member acuity after redeterminations, lagging state rates and new federal eligibility and work-requirement rules could reduce membership and margins; management calls 2026 the trough year.
- Medicare Advantage rates and Stars: Lower Star Ratings for 2027 (about half of members in 4-star plans), CMS risk-adjustment audits and the $935m Q1 2026 accrual show how quickly government decisions move earnings.
- Litigation and regulation: Elevance is suing CMS over 2027 Star Ratings, faces a DOJ-led Medicare Advantage suit, and is exposed to state and federal PBM reform affecting CarelonRx.
- ACA subsidy expiry: Enhanced premium tax credits expired on 31 Dec 2025, raising the risk of a smaller, sicker individual market.
- Partner dependence: CarelonRx relies on CVS Caremark for core PBM services under a contract that runs to 31 Dec 2027, and the group depends on its Blue Cross Blue Shield Association licences.
- Leverage and cyber: About $30.8bn of debt, plus the cyber and data risks that come with holding health records for more than 100 million consumers.
11. Recent Developments
- 06 Nov 2026 — Lawsuit over 2027 Star Ratings. Elevance sued HHS and CMS, arguing CMS used 11 measures without formal rulemaking; it says the ratings cut 2028 quality bonus and rebate payments by about $516m across 12 contracts.
- 22 Oct 2026 — CFO share sale. CFO Mark Kaye sold 10,584 shares for about $4.66m the day after results.
- 21 Oct 2026 — Q3 beat and guidance raised. Adjusted EPS was $6.99 (GAAP $6.27) on operating revenue of $50,440m; 2026 adjusted EPS guidance was raised to at least $29.00, and management guided to at least 12% adjusted EPS growth in 2027.
- 21 Oct 2026 — New Carelon president. Jeff Park was named President of Carelon, effective 01 Dec 2026.
- 20 Oct 2026 — Dividend declared. The board declared a $1.72 quarterly dividend payable 18 Dec 2026.
- 15 Jul 2026 — Q2 results and guidance raise. Adjusted EPS was $7.45 and 2026 adjusted EPS guidance rose to at least $27.00.
12. Key Dates
- 24 Nov 2026 — Next FINRA short-interest release.
- 01 Dec 2026 — Jeff Park starts as President of Carelon.
- 04 Dec 2026 — Ex-dividend and record date for the $1.72 quarterly dividend.
- 18 Dec 2026 — Quarterly dividend payment.
- Expected Jan 2027 — Q4 and FY2026 results with detailed 2027 guidance; date not yet confirmed (FY2025 results were released 28 Jan 2026).
- 31 Dec 2027 — End of the current CVS Caremark PBM services agreement term, which carries a three-year extension option.
A ruling in the Star Ratings lawsuit has no scheduled date.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 12 November 2026
The Cigna Group is a US health services company built around two businesses: Evernorth Health Services, which runs the Express Scripts pharmacy benefit manager and the Accredo specialty pharmacy, and Cigna Healthcare, which provides medical, dental and behavioural benefits mainly to employers. With FY2025 revenue of $274.9bn it is one of the largest companies in the US by sales. The business is in the middle of a shift to a rebate-free pharmacy benefit model and a leadership change, with Brian Evanko CEO since 01 Jul 2026. This report covers the latest filings, including Q3 2026 results released on 05 Nov 2026. Track the shares on our Live Charts, check market-moving events on the Economic Calendar, and join the discussion in the ChartsView Forum.
1. Company Snapshot
| Field | Value |
|---|---|
| Ticker / Exchange | CI / NYSE |
| Headquarters | 900 Cottage Grove Road, Bloomfield, Connecticut |
| Corporate history | Roots traced to 1792; incorporated in Delaware; renamed The Cigna Group in Feb 2023 |
| CEO / Leadership | Brian Evanko, President & CEO since 01 Jul 2026; David M. Cordani, Executive Chair (CEO until 30 Jun 2026); Ann M. Dennison, EVP & CFO |
| Employees | ~67,700 at year-end 2025 (about 88% in the US) |
| Sector | Healthcare / Managed care and pharmacy benefit services |
| Market cap | ~$79.4bn (11 Nov 2026; 263.5m shares x $301.45) |
| FY2025 Revenue | $274,900m total revenues (+11.2% YoY) |
| FY2025 net earnings | GAAP diluted EPS $22.18; adjusted EPS $29.84 (adjusted income from operations per share) |
| Dividend | $1.56 quarterly ($6.24 annualised), up from $1.51 in 2025 |
| Shares outstanding | 263,502,561 (30 Oct 2026, 10-Q cover) |
| Fiscal year end | 31 December |
2. Bull Case vs Bear Case
Bull Case
- Specialty pharmacy momentum: Specialty and Care Services pre-tax income rose 15% in Q3 2026 to $1,064m as more patients moved to lower-cost biosimilars and specialty generics.
- Guidance keeps rising: 2026 adjusted EPS guidance has been raised every quarter, from at least $30.25 in February to at least $30.60 on 05 Nov 2026.
- Long-range targets: At the 30 Sep 2026 Investor Day management set 10% to 14% adjusted EPS compound growth and about $50bn of cumulative operating cash flow through 2030.
- Cigna Healthcare margins: Q3 2026 Cigna Healthcare pre-tax income rose 15% to $1,193m with a medical care ratio of 85.0%, and medical customers grew 2% year to date.
Bear Case
- PBM profit squeeze: Pharmacy Benefit Services pre-tax income fell 22% in Q3 2026 to $765m, and management has called 2027 a trough year for parts of that business.
- Rebate-free transition risk: Moving clients to an upfront-discount, fee-based model by 2028 changes how Express Scripts earns money, and the 10-K says it will weigh on near-term Evernorth earnings.
- Regulatory pressure on PBMs: The FTC settlement, Medicare Part D delinking in the Consolidated Appropriations Act 2026, a new Labor Department disclosure rule and state laws on PBM-owned pharmacies all constrain the model.
- Shrinking customer base: Total customer relationships fell 6% year to date to 177.6m, with pharmacy customers down 5% on expected client departures.
3. Segments & Revenue Mix
FY2025 adjusted revenues by segment, as a percentage of consolidated adjusted revenue of $274,651m. Shares add to more than 100% because of $8,139m of corporate eliminations (mostly Evernorth services provided to Cigna Healthcare).
| Segment | % of revenue | What it is |
|---|---|---|
| Evernorth: Pharmacy Benefit Services | 48.1% ($132,126m, +18%) | Express Scripts PBM: claims processing, pharmacy networks, formulary management and home delivery for employers, health plans and government clients. FY2025 pre-tax adjusted income $3,506m. |
| Evernorth: Specialty and Care Services | 37.4% ($102,827m, +14%) | Accredo specialty pharmacy, specialty distribution (including Quallent private-label biosimilars) and care services. FY2025 pre-tax adjusted income $3,715m. |
| Cigna Healthcare | 17.2% ($47,163m, -11%) | Medical, dental, behavioural and stop-loss coverage for US employers, individuals and international customers. Revenue fell after the Medicare business sale; excluding divested units it grew 7%. FY2025 pre-tax adjusted income $4,153m. |
| Other operations | 0.2% ($674m) | Smaller businesses reported outside the two main segments. FY2025 pre-tax adjusted income $89m. |
| Corporate and eliminations | -3.0% (-$8,139m) | Intersegment eliminations. |
Cigna sold its Medicare Advantage, Part D, Medicare supplemental and CareAllies businesses to Health Care Service Corporation (HCSC), with the sale closing on 19 Mar 2025.
4. Business Model & Moat
How it makes money. Evernorth earns fees and spreads for managing prescription drug benefits and earns product margins dispensing specialty drugs through Accredo; it generated about 85% of FY2025 revenue but on thin margins. Cigna Healthcare collects premiums from fully insured customers and administrative fees from self-funded employers, earning the difference between premiums and medical costs (a medical care ratio of 84.4% in FY2025).
Scale as the moat. Express Scripts is one of the three largest US PBMs alongside CVS Caremark and Optum Rx. Purchasing scale with drugmakers and pharmacies, and contracts with its three largest clients renewed through the end of the decade, are hard for smaller rivals to match.
Rebate-free model. Announced on 27 Oct 2025, the new model passes drugmaker discounts to patients at the counter, pays pharmacies on a cost-plus basis, and replaces rebate guarantees with a stated administrative fee. Cigna Healthcare's fully insured plans adopt it from 2027, and it becomes Evernorth's standard offering ("Signature") from 2028.
Capital allocation. Cigna paid $1,236m of dividends in the first nine months of 2026, has repurchased about $500m of stock in 2026 (versus $3.6bn in 2025), and targets about 40% debt-to-capital by end-2026 (41.8% at 30 Sep 2026).
5. Financial Health
Annual figures from Cigna's 10-K filings, SEC XBRL data and Q4 earnings releases.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| FY2021 | $174,069m | +8.5% | $15.75 | $20.47 | $4.00 | $31,125m |
| FY2022 | $180,518m | +3.7% | $21.41 | $23.36† | $4.48 | $28,100m |
| FY2023 | $195,265m | +8.2% | $17.39 | $25.09 | $4.92 | $28,155m |
| FY2024 | $247,121m | +26.6% | $12.12 | $27.33 | $5.60 | $28,937m |
| FY2025 | $274,900m | +11.2% | $22.18 | $29.84 | $6.04 | $30,871m |
† FY2022 adjusted EPS recast to $23.36 (from $23.27) and GAAP EPS shown as recast for the 2023 change in insurance contract accounting; FY2021 GAAP EPS is the recast $15.75 ($15.73 as first reported). FY2024 GAAP EPS includes a $9.53 per share non-cash investment loss. Adjusted EPS is adjusted income from operations per share. Long-term debt excludes the current portion ($592m short-term debt at end-2025).
Quarterly results, most recent first.
| Quarter / Half | Revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q3 2026 | $73,683m (+6%) | $7.98 | $5.47 |
| Q2 2026 | $71,668m (+7%) | $7.78 | $6.29 |
| Q1 2026 | $68,494m (+5%) | $7.79 | $6.26 |
| Q3 2025 | $69,748m | $7.83 | $6.98 |
| Q2 2025 | $67,178m | $7.20 | $5.71 |
| Q1 2025 | $65,502m | $6.74 | $4.85 |
| 9M 2026 total | $213,845m | $23.55 | $18.02 |
| FY2025 total | $274,900m | $29.84 | $22.18 |
Q3 2026 GAAP EPS fell year on year because Q3 2025 included a $241m after-tax gain on a business sale. Q2 2026 growth is computed from reported revenue.
Cash flow and balance sheet. FY2025 operating cash flow was $9,601m, capex (property and equipment purchases, net) $1,212m, and depreciation and amortisation $2,775m. Nine-month 2026 operating cash flow was $3,281m against company guidance of about $9.0bn for the full year. At 30 Sep 2026 total debt was $31,142m ($2,293m short-term including $500m of commercial paper, plus $28,849m long-term), against cash of $6,186m and short-term investments of $1,109m. In Sep 2025 Cigna issued $4.5bn of senior notes, partly to repay a $2.0bn term loan used for the $3.5bn Shields Health Solutions investment.
6. Valuation Snapshot
Raw metrics, November 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Share price | $301.45 (11 Nov 2026 close) |
| Market cap | ~$79.4bn (263.5m shares x $301.45) |
| 52-week high | $318.05 (as of 06 Nov 2026) |
| 52-week low | $255.53 (as of 06 Nov 2026) |
| Trailing P/E (GAAP) | ~13.3x (TTM GAAP EPS $22.66 = FY2025 $22.18 - 9M 2025 $17.54 + 9M 2026 $18.02). On TTM adjusted EPS of $31.62 the multiple is ~9.5x. |
| P/E (forward) | ~9.9x on company 2026 adjusted EPS guidance of at least $30.60 |
| P/S (TTM) | ~0.28x (market cap ~$79.4bn / TTM revenues $286,317m) |
| P/FCF | ~9.5x (market cap ~$79.4bn / FCF ~$8,389m; FCF = operating CF $9,601m - capex $1,212m per FY2025 cash flow statement). Nine-month 2026 operating cash flow was lower at $3,281m. |
| Enterprise value | ~$103.3bn (market cap ~$79.4bn + total debt $31,142m - cash $6,186m - short-term investments $1,109m per 30 Sep 2026 balance sheet) |
| EV/EBITDA (TTM) | ~8.2x (EV ~$103.3bn / TTM EBITDA ~$12,669m; income from operations $9,775m + D&A $2,894m, both TTM to Q3 2026 from the cash flow statement and income statement) |
| Dividend yield | ~2.1% ($6.24 annualised / $301.45) |
| Short interest (% of float) | ~2.4% (6.23m shares short, 30 Oct 2026 FINRA settlement via Equibles; ORTEX showed 2.43% of free float on 23 Oct 2026) |
| Days to cover | 4.24 (30 Oct 2026 settlement; 4.48 on 15 Oct) |
7. What Are They Building
- "Lead to One" strategy: Presented at the 30 Sep 2026 Investor Day, it centres on leadership in complex care, alongside "Accelerate to One", a $3bn multi-year programme covering process modernisation, AI-enabled tools for staff and vendor discipline.
- Rebate-free pharmacy benefits: Express Scripts is moving clients to upfront point-of-sale discounts, cost-plus pharmacy pay and a flat administrative fee, standard from 2028 under the "Signature" name.
- Biosimilars through Quallent: Evernorth has offered a Humira biosimilar at $0 out of pocket since 2024 and a Stelara biosimilar at $0 through Accredo from 2025, each priced more than 80% below the brand's list price.
- GLP-1 programmes: EncircleRx offers employers a cost cap or savings guarantee on GLP-1 spend with lifestyle partners, EnGuide Pharmacy supports GLP-1 patients, and a $200 a month member cap applies to key GLP-1 drugs.
- Health Sense: Announced 06 Oct 2026, a personalised guidance and clinical support model rolling out from early 2027, first for oncology and cardiometabolic patients.
- Portfolio moves: a $3.5bn preferred-stock investment in Shields Health Solutions (Sep 2025), an exit from ACA individual plans from 01 Jan 2027 (about 369,000 lives in 11 states), and a strategic review of eviCore announced 30 Apr 2026.
8. Competitive Landscape
| Peer | Market cap (November 2026) | Key 2025 metric |
|---|---|---|
| UnitedHealth Group (UNH) | ~$363.0bn (11 Nov 2026, Equibles) | FY2025 revenue $447.6bn; diluted EPS $13.23 (SEC XBRL) |
| CVS Health (CVS) | ~$114.5bn (11 Nov 2026, Equibles) | FY2025 revenue $402.1bn; diluted EPS $1.39 (SEC XBRL) |
| Elevance Health (ELV) | ~$92.8bn (10 Nov 2026, Equibles) | FY2025 revenue $199.1bn; diluted EPS $25.21 (SEC XBRL) |
| Humana (HUM) | ~$53.6bn (11 Nov 2026, Equibles) | FY2025 revenue $129.7bn; diluted EPS $9.84 (SEC XBRL) |
| Centene (CNC) | ~$34.5bn (09 Nov 2026, Equibles) | FY2025 revenue $194.8bn; diluted EPS -$13.53 (SEC XBRL) |
In pharmacy benefits Express Scripts competes mainly with CVS Caremark and UnitedHealth's Optum Rx. CVS announced on 04 Nov 2026 that it will separate its retail pharmacy from its PBM and insurance businesses.
9. Insider Activity
Brian Evanko became CEO on 01 Jul 2026, succeeding David Cordani, who remains Executive Chair. The table lists 2026 Form 4 open-market and option-linked sales; there were no open-market purchases by insiders in 2026.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| David Cordani (then Chairman & CEO) | 12 May 2026 | Option exercise and sale | 201,878 | ~$292.82 (wtd avg) | ~$59.1m | 10b5-1 (adopted 06 Feb 2026) |
| Nicole S. Jones (EVP, CAO & CHRO) | 18 Aug 2026 | Sale | 2,677 | $279.61 | ~$0.75m | 10b5-1 |
| Nicole S. Jones | 04 Aug 2026 | Option exercise and sale | 19,436 | $276.27 | ~$5.37m | 10b5-1 (adopted 04 May 2026) |
| Everett Neville (EVP) | 03 Sep 2026 | Sale | 617 | $284.05 | ~$0.18m | 10b5-1 |
| Jamie Kates (Chief Accounting Officer) | 12 Jun 2026 | Option exercise and sale | 899 | $298.61 | ~$0.27m | Not 10b5-1 |
| Nicole S. Jones | 02 Mar 2026 | Sale | 2,307 | $288.91 | ~$0.67m | 10b5-1 |
| Everett Neville | 02 Mar 2026 | Sale | 1,719 | $288.91 | ~$0.50m | 10b5-1 |
Source: SEC Form 4 filings for CIK 1739940. Grants, phantom units and tax withholding are excluded. The Q3 2026 10-Q states no director or officer adopted, changed or ended a 10b5-1 plan in the quarter.
10. Key Risks
- PBM regulation: Medicare Part D delinking under the Consolidated Appropriations Act 2026, the Labor Department's PBM disclosure rule (plan years from 01 Jul 2027), state limits on PBM-owned pharmacies such as Tennessee's, and the FTC order with a three-year monitor all narrow how Express Scripts can earn money.
- Business model transition: The rebate-free model replaces rebate economics with fees; Pharmacy Benefit Services profit is already down sharply in 2026 and management expects 2027 to be a trough year for part of it.
- Client concentration: Large renewals with the top three clients run to the end of the decade at renewal pricing, and pharmacy customers are down 5% year to date.
- Litigation: Antitrust and underpayment suits from pharmacies and other claims led to $126m of pre-tax litigation charges in the first nine months of 2026.
- Drug trend and pipeline: Slower GLP-1 volumes, employers dropping weight-loss coverage and a maturing biosimilar wave (Humira, Stelara, Revlimid) could slow Specialty and Care growth.
- Medical costs: A rise in medical cost trend or stop-loss claims would push the medical care ratio (85.0% in Q3 2026) above guidance of 84.2% plus or minus 25bp.
- Leverage and investments: $31.1bn of debt, 41.8% debt-to-capital, and a history of strategic write-downs (VillageMD in 2024) add risk to the $3.5bn Shields investment and the $3bn modernisation programme.
11. Recent Developments
- 10 Nov 2026 — UBS healthcare conference. Management reaffirmed its 2030 targets, described 2027 as a trough year for part of Pharmacy Benefit Services and said it targets about 40% leverage by end-2026 (per conference coverage).
- 05 Nov 2026 — Q3 results beat, outlook raised. Revenue rose 6% to $73,683m and adjusted EPS rose to $7.98 from $7.83; 2026 adjusted EPS guidance was raised to at least $30.60.
- 04 Nov 2026 — CVS to split. Rival CVS Health said it will separate its retail pharmacy from its PBM and insurance businesses.
- 29 Oct 2026 — PBM disclosure rule. The Labor Department finalised a rule requiring PBMs to disclose compensation to large self-insured employer plans, effective for plan years from 01 Jul 2027.
- 28 Oct 2026 — Dividend declared. The board declared a $1.56 quarterly dividend payable 17 Dec 2026.
- 06 Oct 2026 — Health Sense launched. Cigna Healthcare introduced a personalised guidance and clinical support model rolling out from early 2027.
- 30 Sep 2026 — Investor Day. Cigna set out "Lead to One", 2030 targets of 10% to 14% adjusted EPS growth and about $50bn of operating cash flow, and a $3bn modernisation programme.
12. Key Dates
- 24 Nov 2026 — Next FINRA short-interest release.
- 03 Dec 2026 — Record and ex-dividend date for the $1.56 quarterly dividend.
- 17 Dec 2026 — Quarterly dividend payment.
- 01 Jan 2027 — Exit from ACA individual plans takes effect; Cigna Healthcare fully insured plans move to the rebate-free pharmacy model.
- Expected Feb 2027 — Q4 and FY2026 results with full 2027 guidance; date not yet confirmed (FY2025 results were released 05 Feb 2026).
- 01 Jul 2027 — Labor Department PBM disclosure rule applies to plan years beginning on or after this date.
- Expected Jan 2028 — Rebate-free "Signature" model becomes Evernorth's standard pharmacy benefit offering.
Tennessee's law on PBM-owned pharmacies, which Express Scripts is challenging in court, is due to take effect in July 2028.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 9 November 2026
Boston Scientific Corporation (NYSE: BSX) makes medical devices used in heart, vascular, digestive, urological and nerve procedures, including the FARAPULSE pulsed field ablation system for atrial fibrillation and the WATCHMAN left atrial appendage closure device. In 2025 net sales rose 19.9% to $20,074m (15.8% organic), GAAP EPS was $1.94 and adjusted EPS $3.06. 2026 has been much harder: a cyberattack detected on 25 Aug 2026 disrupted manufacturing and shipping worldwide, electrophysiology and WATCHMAN sales fell in Q3 as competition grew, and on 28 Oct 2026 the company cut its full-year guidance for the third time, to about 3.75% organic sales growth and adjusted EPS of $3.16 to $3.18. Its $14.5bn purchase of Penumbra is now expected to close in early 2027. Every figure here comes from Boston Scientific's own releases and SEC filings.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Boston Scientific Corporation |
| Ticker / Exchange | BSX / NYSE |
| Sector | Healthcare (medical devices) |
| CEO / Leadership | Mike Mahoney (Chairman & CEO); Jon Monson (EVP & CFO since Jun 2025); Joseph Fitzgerald becomes COO on 01 Jan 2027 |
| Employees | About 59,000 at 31 Dec 2025, about 60% outside the US (FY2025 10-K) |
| Headquarters | Marlborough, Massachusetts |
| Founded | 1979 |
| Fiscal year end | 31 December |
| Revenue (FY2025) | $20,074m net sales (+19.9% reported, +15.8% organic); trailing four quarters to 30 Sep 2026 $21,070m |
| Net income (FY2025) | GAAP diluted EPS $1.94; adjusted EPS $3.06 |
| Market cap | ~$62.0bn ($42.75 close on 06 Nov 2026 × 1,449.5m shares outstanding at 29 Oct 2026) |
| Dividend | None — the company does not pay a cash dividend |
2. Investment Thesis: Bull vs Bear
Bull Case
- FARAPULSE built a large franchise fast: Electrophysiology sales grew from $800m in 2023 to $3,325m in 2025, driven by the FARAPULSE pulsed field ablation system, with new FARAPOINT and FARASTAR products approved since Q4 2025.
- Strong WATCHMAN trial data: CHAMPION-AF, comparing WATCHMAN FLX with blood thinners as a first-line option, met all primary and secondary endpoints in Mar 2026, and SIMPLAAFY met its primary endpoints on 02 Nov 2026.
- Insiders bought after the fall: CEO Mike Mahoney bought 186,240 shares for about $9.0m on 03 Aug 2026, and four directors also made open-market purchases between May and Aug 2026.
- Still growing and cash generative: FY2026 sales are still guided up about 4.25% reported, operating cash flow was $4,534m in 2025, and Neuromodulation grew 13.1% in Q3 2026.
Bear Case
- Three guidance cuts: FY2026 organic growth guidance has fallen from 10–11% in Feb 2026 to about 3.75%, and adjusted EPS guidance from $3.43–$3.49 to $3.16–$3.18; Q4 2026 sales are guided down 1–3%.
- Losing share in ablation: Electrophysiology sales fell about 5.7% in Q3 2026 to $816m, and the 10-Q cites increased competition from rival pulsed field ablation systems.
- WATCHMAN slowing: WATCHMAN sales fell about 5.9% in Q3 2026 to $482m, which the company put down to a deceleration in the left atrial appendage closure market.
- Cyberattack damage: The incident detected on 25 Aug 2026 disrupted manufacturing, ordering and shipping, cut the Q3 gross margin by 1.7 points and was disclosed as material.
- Quality problems: The FDA classed recalls of AXIOS stents, Infinion CX spinal cord stimulator leads and Imager II angiographic catheters as Class I in 2026.
3. Business Segments
Boston Scientific reports two segments, MedSurg and Cardiovascular. Figures are FY2025 net sales from the FY2025 10-K; percentages are of total net sales of $20,074m.
| Segment | % of revenue | What it is |
|---|---|---|
| Cardiovascular — Interventional Cardiology & Vascular Therapies | 23.1% ($4,639m) | Stents, balloons, intravascular lithotripsy, structural heart and vascular devices used to open blocked arteries and veins. |
| Cardiovascular — Electrophysiology | 16.6% ($3,325m) | Ablation catheters, mapping and the FARAPULSE pulsed field ablation system for heart rhythm disorders such as atrial fibrillation. |
| Cardiovascular — Cardiac Rhythm Management | 11.6% ($2,332m) | Pacemakers, defibrillators and cardiac diagnostics. |
| Cardiovascular — WATCHMAN | 9.8% ($1,958m) | Left atrial appendage closure implant that lowers stroke risk in atrial fibrillation patients as an alternative to long-term blood thinners. |
| Cardiovascular — Interventional Oncology & Embolization | 5.0% ($996m) | Devices that treat tumours and block blood vessels from inside the body. |
| MedSurg — Endoscopy | 14.5% ($2,916m) | Devices for diagnosing and treating digestive and lung conditions, including AXIOS stents. |
| MedSurg — Urology | 13.5% ($2,709m) | Kidney stone, prostate, pelvic health and men's health products. |
| MedSurg — Neuromodulation | 6.0% ($1,199m) | Spinal cord and deep brain stimulation systems for chronic pain and movement disorders. |
The US was $12,864m (64%) of FY2025 sales. From 01 Jan 2027 the company will report three segments: Interventional Therapies, Rhythm Solutions and MedSurg.
4. Business Model & Moat
How it makes money. Boston Scientific sells single-use and implantable devices to hospitals and clinics; sales rise with procedure volumes and with new products that win share. It spent $2,052m (10.2% of sales) on research and development in 2025 and runs 13 principal manufacturing plants.
Category leadership. WATCHMAN leads left atrial appendage closure, and FARAPULSE was the leading US pulsed field ablation system through 2024. The company backs its devices with large clinical trials such as ADVENT, AVANT GUARD, OPTION and CHAMPION-AF, which support label expansions and physician adoption.
Buying growth. Boston Scientific adds technologies through many tuck-in deals: in 2025 it bought Cortex, Bolt Medical, Intera Oncology, SoniVie, Anrei Medical and Elutia's BioEnvelope business, and in 2026 Valencia Technologies, Nalu Medical and Scivita Medical.
Where the moat is tested. Medtronic, Johnson & Johnson and Abbott have all launched pulsed field ablation systems, and US purchasing data from Qsight suggest Boston Scientific's share of US pulsed field ablation spend fell from about 83% through 2024 to about 41% in early 2026.
5. Financial Health
Annual figures come from Boston Scientific's fourth-quarter earnings releases and 10-K filings, cross-checked against SEC XBRL data. Revenue is net sales. Long-term debt is the year-end non-current balance including finance leases.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| FY2021 | $11,888m | +19.9% | $0.69 | $1.63 | Nil | $8,804m |
| FY2022 | $12,682m | +6.7% | $0.45 | $1.71 | Nil | $8,915m |
| FY2023 | $14,240m | +12.3% | $1.07 | $2.05 | Nil | $8,571m |
| FY2024 | $16,747m | +17.6% | $1.25 | $2.51 | Nil | $8,968m |
| FY2025 | $20,074m | +19.9% | $1.94 | $3.06 | Nil | $11,137m |
FY2021 growth is against FY2020 net sales of $9,913m. Adjusted EPS excludes amortisation, acquisition, restructuring, litigation and other items, as defined by Boston Scientific. The company did not pay cash dividends in any year shown.
Quarterly results, most recent first.
| Quarter / Half | Revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q3 2026 (to 30 Sep 2026) | $5,138m | $0.73 | $0.40 |
| Q2 2026 (to 30 Jun 2026) | $5,442m | $0.86 | $0.61 |
| Q1 2026 (to 31 Mar 2026) | $5,203m | $0.80 | $0.90 |
| Q4 2025 (to 31 Dec 2025) | $5,286m | $0.80 | $0.45 |
| Q3 2025 (to 30 Sep 2025) | $5,065m | $0.75 | $0.51 |
| Q2 2025 (to 30 Jun 2025) | $5,061m | $0.75 | $0.53 |
| Q1 2025 (to 31 Mar 2025) | $4,663m | $0.75 | $0.45 |
| FY2025 total | $20,074m | $3.06 | $1.94 |
Q1 2026 GAAP EPS includes a $320m deferred tax benefit, and Q2 2026 an $83m tariff refund. The 2025 quarterly adjusted EPS figures add up to $3.05 because of rounding. Q3 2026 gross margin was 66.7% against 69.9% a year earlier.
Cash flow and balance sheet. Operating cash flow was $4,534m in 2025 and $2,870m in the first nine months of 2026; capital spending was $876m and $552m. Depreciation and amortisation (including amortisation of acquired intangibles) was $1,368m in 2025 and $1,067m in the nine months. At 30 Sep 2026 the company had long-term debt of $10,909m, current debt of $1,044m (including $1,029m of commercial paper), cash of $609m and stockholders' equity of $25,630m. A $6bn term loan agreed on 26 Feb 2026 can only be drawn when the Penumbra deal closes. Follow the shares on ChartsView Live Charts.
6. Valuation
Raw metrics, November 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$62.0bn ($42.75 close on 06 Nov 2026 × 1,449.5m shares outstanding) |
| Trailing P/E (GAAP) | ~18.1x ($42.75 / GAAP diluted EPS of $2.36 over the four quarters to 30 Sep 2026). On adjusted EPS of $3.19 for the same period the multiple is ~13.4x. |
| P/E (forward) | ~13.5x ($42.75 / midpoint of management's FY2026 adjusted EPS guidance of $3.16–$3.18) |
| P/S (TTM) | ~2.9x (~$62.0bn / net sales of $21,070m over the four quarters to 30 Sep 2026) |
| Enterprise value | ~$73.3bn (market cap ~$62.0bn + total debt $11,953m (long-term $10,909m + current $1,044m) − cash $609m, per 30 Sep 2026 balance sheet) |
| EV/EBITDA (TTM) | ~13.7x (EV ~$73.3bn / EBITDA ~$5,364m; EBITDA = operating income $3,932m + depreciation and amortisation $1,432m over the four quarters to 30 Sep 2026, using the total D&A figure that includes amortisation of acquired intangibles) |
| P/FCF | ~18.6x (market cap ~$62.0bn / FCF ~$3.33bn; FCF = operating cash flow $4,234m − capex $903m over the four quarters to 30 Sep 2026) |
| Dividend yield | Nil — no cash dividend |
| 52-week high | $105.65 (13 Nov 2025, intraday) |
| 52-week low | $39.57 (28 Oct 2026, intraday, the day of Q3 results) |
| Short interest (% of float) | ~2.81% (40.7m shares at settlement 15 Oct 2026, Yahoo Finance from exchange data) |
| Days to cover | ~2.2 (15 Oct 2026, Yahoo Finance) |
7. What Are They Building
Penumbra. Announced on 15 Jan 2026, the deal values Penumbra at $374 a share, about $14.5bn, paid roughly 73% in cash and 27% in Boston Scientific shares. Penumbra holders approved it on 06 May 2026, but the FTC issued a Second Request on 16 Mar 2026, and the Q3 10-Q now expects completion in early 2027. Penumbra will join the new Interventional Therapies segment.
Next-generation ablation. The FARAPOINT focal pulsed field ablation catheter was approved in Q4 2025 and the FARASTAR generator in Jan 2026; the FARADIGM pivotal trial of FARAFLEX has started enrolling. ADVENT four-year data and the AVANT GUARD trial in persistent atrial fibrillation were positive.
WATCHMAN expansion. After CHAMPION-AF and SIMPLAAFY, the company is pursuing wider use of WATCHMAN, and the Elite AF trial of the next-generation WATCHMAN Elite device has started enrolling. No FDA label change based on CHAMPION-AF had been announced as of early Nov 2026.
Other deals and stakes. In 2026 Boston Scientific closed Valencia Technologies (tibial nerve stimulation for urge incontinence), Nalu Medical (about $523m, peripheral nerve stimulation) and Scivita Medical ($213m, endoscopes in China), agreed to buy Jiangsu TingSN (about $250m, intravascular ultrasound) and invested $1.5bn for about 34% of MiRus, with an option on its SIEGEL TAVR heart valve business.
Reorganisation. A restructuring plan approved on 21 Jul 2026 carries $700–800m of pre-tax charges and targets about $500m of gross annual savings, and the company completed a $2bn accelerated share repurchase in Q2 2026.
8. Competitive Landscape
| Peer | Market cap (November 2026) | Key 2025 metric |
|---|---|---|
| Johnson & Johnson (JNJ) | ~$665.0bn for the whole group ($276.22 close on 06 Nov 2026) | FY2025 MedTech sales $33,792m, +6.1% (Q4 2025 release) |
| Abbott (ABT) | ~$190.4bn ($109.93 close on 06 Nov 2026) | FY2025 sales about $44.3bn; adjusted EPS $5.15 (Q4 2025 release) |
| Medtronic (MDT) | ~$130.2bn ($101.80 close on 06 Nov 2026) | FY2026 (to 24 Apr 2026) revenue $36.4bn, +8.4%; Q4 cardiac ablation solutions +78% (Q4 FY2026 release) |
| Stryker (SYK) | ~$124.1bn ($325.87 close on 06 Nov 2026) | FY2025 net sales about $25.1bn, +11.2% (FY2025 results release) |
| Edwards Lifesciences (EW) | ~$58.7bn ($102.14 close on 06 Nov 2026) | FY2025 sales +11.5%, TAVR about $4.5bn (Q4 2025 release); its Ecliptis left atrial appendage system was cleared by the FDA in Jun 2026 |
Medtronic, Johnson & Johnson and Abbott compete directly in pulsed field ablation, and Edwards is entering left atrial appendage closure. Boston Scientific's shares closed at $42.75 on 06 Nov 2026, against $95.35 at the end of 2025. Discuss the sector on the ChartsView Forum.
9. Leadership & Insider Activity
Mike Mahoney is Chairman and CEO, Jon Monson has been CFO since Jun 2025, and Joseph Fitzgerald becomes Chief Operating Officer on 01 Jan 2027, when MedSurg and Asia-Pacific head Arthur Butcher retires. After the share price fell, the CEO and four directors bought shares on the open market; earlier in the year the CEO sold under a Rule 10b5-1 plan. Transactions from SEC Form 4 filings (weighted-average prices):
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Susan Morano (Director) | 25 Aug 2026 | Buy | 2,040 | $49.22 | ~$0.10m | Open market |
| David Habiger (Director) | 05 Aug 2026 | Buy | 2,100 | $47.59 | ~$0.10m | Open market |
| Mike Mahoney (Chairman & CEO) | 03 Aug 2026 | Buy | 186,240 | $48.33 | ~$9.0m | Open market |
| Edward Ludwig (Director) | 31 Jul 2026 | Buy | 5,000 | $45.48 | ~$0.23m | Open market |
| Edward Ludwig (Director) | 20 May 2026 | Buy | 3,580 | $56.68 | ~$0.20m | Open market |
| Cheryl Pegus (Director) | 20 May 2026 | Buy | 1,770 | $56.49 | ~$0.10m | Open market |
| David Habiger (Director) | 20 May 2026 | Buy | 2,250 | $55.92 | ~$0.13m | Open market |
| Mike Mahoney (Chairman & CEO) | 02 Feb 2026 | Sell | 159,701 | $93.49 | ~$14.9m | 10b5-1 (adopted 29 Aug 2025) |
Other 2026 filings were annual stock awards, tax withholding, 401(k) plan transactions and gifts, including 386,755 shares Mahoney gifted to a family trust on 28 May 2026.
10. Key Risks
- Cybersecurity incident (Operational): The attack detected on 25 Aug 2026 disrupted manufacturing, order processing and shipping worldwide; an 8-K under Item 1.05 said it was likely to have a material impact on Q3 and FY2026, and the timing of full recovery is uncertain.
- Ablation competition (Competitive): Medtronic, Johnson & Johnson and Abbott now sell pulsed field ablation systems; Electrophysiology sales fell in Q3 2026 and the company cites share loss and pricing pressure in China.
- WATCHMAN demand (Commercial): WATCHMAN sales fell in Q3 2026, Edwards has a newly cleared rival device, and wider use depends on label changes and Medicare coverage that are still pending.
- Penumbra deal (Financial): The FTC review has pushed closing to early 2027; the roughly $11bn cash portion will be funded partly with new debt, adding integration risk on top of many smaller 2025–2026 deals.
- Product quality (Regulatory): Class I recalls in 2026 of AXIOS stents, Infinion CX leads (1,081 serious injuries reported as of 27 May 2026) and Imager II catheters could bring further costs and FDA scrutiny.
- China pricing (Regulatory): Volume-based procurement in China is cutting prices in Endoscopy and the Urology stone business.
- Litigation (Legal): Litigation-related charges were $157m in the first nine months of 2026 and $194m in Q4 2025, and transvaginal mesh claims are still pending.
- Tariffs and currency (Macro): About 36% of sales are outside the US, so currency moves shift reported growth, and changing US tariff policy affects costs.
11. Recent Developments
- 02 Nov 2026 — SIMPLAAFY trial positive. The WATCHMAN SIMPLAAFY trial met its primary endpoints. The Q3 10-Q filed the same day said the Penumbra deal is now expected to close in early 2027.
- 28 Oct 2026 — Q3 results and third guidance cut. Net sales rose 1.5% to $5,138m, below July guidance of 3–5%; adjusted EPS was $0.73 and GAAP EPS $0.40. FY2026 guidance was cut to about 3.75% organic growth and adjusted EPS of $3.16–$3.18, and the shares hit a 52-week low of $39.57 intraday.
- 07 Oct 2026 — New COO and segments. Joseph Fitzgerald was named Chief Operating Officer from 01 Jan 2027, when the company moves to three reporting segments.
- 25 Sep 2026 — Class I recall. The FDA classed the recall of Imager II angiographic catheters as Class I.
- 11 Sep 2026 — TingSN agreement. Boston Scientific agreed to buy Jiangsu TingSN, a Chinese maker of intravascular and intracardiac ultrasound, for about $250m upfront plus up to $75m.
- 08 Sep 2026 — Cyberattack judged material. An 8-K said the incident was likely to have a material impact and the company was unlikely to meet its prior Q3 and full-year guidance.
- 26 Aug 2026 — Cyberattack disclosed. The company said an attack detected on 25 Aug 2026 had disrupted operations globally.
- 03 Aug 2026 — CEO buys shares. Mike Mahoney bought 186,240 shares for about $9.0m, with directors Habiger and Ludwig also buying.
Macro data such as US inflation and interest-rate decisions are on the ChartsView Economic Calendar.
12. Key Dates
- 11 Nov 2026 — Presentation at the Stifel 2026 Healthcare Conference (webcast).
- Expected Dec 2026 — Completion of the Jiangsu TingSN acquisition (expected in Q4 2026).
- 01 Jan 2027 — Joseph Fitzgerald becomes COO, three-segment reporting begins and Arthur Butcher retires.
- Expected Feb 2027 — Q4 and full-year 2026 results (Q4 2025 results were released on 04 Feb 2026; date not yet confirmed).
- Expected early 2027 — Completion of the Penumbra acquisition, subject to the FTC review.
- Expected Apr 2027 — Annual shareholder meeting (the 2026 meeting was held on 30 Apr 2026).
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 8 August 2026
Novo Nordisk spent three years as the most valuable company in Europe and has spent the last eighteen months finding out what happens when a near-monopoly turns into a duopoly. Sales grew 25% in FY2024 and 6.4% in FY2025. The share price roughly halved from its peak, the chief executive was replaced, the board chair and several directors were removed at an extraordinary general meeting, and roughly 9,000 roles were cut. Underneath the drama the company still sold DKK 309bn of medicine in FY2025, generated DKK 119bn of operating cash flow, and launched the first oral GLP-1 for weight management. This report sets out the reported figures, the balance sheet after the Catalent-financed debt build, the valuation arithmetic and the risks, without opinions on whether the shares are cheap or expensive. For live price action see our Live Charts.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Novo Nordisk A/S |
| Exchange / Ticker | New York Stock Exchange, NVO (American Depositary Receipt, one ADR equals one B share); Nasdaq Copenhagen, NOVO-B |
| Sector / Industry | Healthcare — pharmaceuticals, focused on diabetes, obesity and rare disease |
| Headquarters | Novo Allé 1, 2880 Bagsværd, Denmark |
| Founded | 1923 |
| Reporting currency | Danish kroner (DKK), IFRS. The ADR trades in US dollars |
| CEO / Leadership | Maziar "Mike" Doustdar, President and Chief Executive Officer since 7 August 2025; Karsten Munk Knudsen, Chief Financial Officer; Martin Holst Lange, Chief Scientific Officer and head of Research and Development; Lars Rebien Sørensen, Chair of the Board since November 2025 |
| Employees | 68,794 full-time equivalents at 31 December 2025, down from 76,302 a year earlier after the September 2025 restructuring. Approximately 66,700 people in 80 countries as stated in the 4 August 2026 results announcement |
| Revenue (FY2025) | DKK 309,064m net sales, up 6.4% as reported and 10.3% at constant exchange rates |
| Net profit (FY2025) | DKK 102,434m, with operating profit of DKK 127,658m and an operating margin of 41.3% |
| Market capitalisation | Approximately DKK 1,309bn, equivalent to roughly $197bn (early August 2026) |
| Controlling shareholder | Novo Holdings A/S, wholly owned by the Novo Nordisk Foundation, holds the unlisted A shares carrying 100 votes each and controls a majority of votes |
| Fiscal year end | 31 December |
2. Bull and Bear Case
Bull Case
- The oral GLP-1 franchise is now real and scaling: the Wegovy pill, oral semaglutide 25mg, was approved by the FDA on 22 December 2025 and launched in the US on 5 January 2026. By 17 July 2026 it had passed five million US prescriptions and more than 265,000 weekly scripts, with EMA approval granted in July 2026 and EU rollout planned for the second half of 2026.
- Guidance has been raised twice this year: the FY2026 outlook set on 3 February 2026 of minus 5% to minus 13% at constant exchange rates was lifted to minus 4% to minus 12% in May and again to 0% to minus 6% on 4 August 2026. The direction of travel on management's own numbers has improved every quarter of 2026 so far.
- Cash generation remains exceptional: FY2025 operating cash flow was DKK 119,102m on sales of DKK 309,064m, a 38.5% conversion rate, while operating margin held at 41.3%. This is a business that funds a DKK 60bn annual capital programme and a DKK 16.7bn dividend out of operating cash.
- Capacity constraint is being solved rather than rationed: capital expenditure on property, plant and equipment rose 28% to DKK 60,140m in FY2025, funding API and fill-finish expansion at Kalundborg, Clayton in North Carolina, and the three former Catalent sites at Anagni, Brussels and Bloomington, which begin ramping from 2026.
- The pipeline still has multiple independent shots: CagriSema has been submitted to the FDA for weight management with a decision expected around the turn of 2026 and 2027; the amycretin phase 3 AMAZE programme started in Q1 2026; Mim8 in haemophilia is under review in both the US and EU; and the Akero acquisition adds a phase 3 FGF21 analogue in MASH.
Bear Case
- Eli Lilly is winning the obesity market: Lilly's Mounjaro and Zepbound generated $36.5bn of combined FY2025 sales, and in Q2 2026 alone Mounjaro grew 91% year on year. Novo's global diabetes value market share fell 3.6 percentage points to 30.1% in the year to November 2025.
- US pricing has been structurally reset downwards: the November 2025 most-favoured-nation agreement with the US administration takes Wegovy and Ozempic to roughly $350 a month through TrumpRx and $245 a month for Medicare, with a $199 introductory price. That is a permanent reduction in realised US revenue per prescription, not a one-off rebate.
- The patent cliff has already started outside the US: the semaglutide compound patent lapsed in Canada and generics from Dr. Reddy's, Sandoz, Apotex and Teva were approved between January and April 2026, making Canada the first G7 market with generic semaglutide. Similar exposure exists in India, China, Brazil and Turkey. US protection runs to December 2031.
- The pipeline has produced two high-profile misses: the EVOKE phase 3 Alzheimer's trials of oral semaglutide failed to show a statistically significant reduction in disease progression, and on 31 July 2026 the ZEUS trial of ziltivekimab missed its primary cardiovascular endpoint with a hazard ratio of 0.99. The shares fell 8.8% on the ZEUS news and a DKK 6.3bn impairment followed.
- The balance sheet is no longer pristine: total borrowings rose from DKK 27,006m at the end of FY2023 to DKK 102,787m at FY2024 and DKK 130,958m at FY2025, following the debt-financed purchase of the Catalent fill-finish sites. Gross margin fell from 84.7% to 81.0% partly on the associated depreciation and amortisation.
3. Segments and Revenue Breakdown
Novo Nordisk reports two segments. The franchise lines below are the disclosed product categories within them, taken from the FY2025 results announcement. All figures are DKK millions for the year ended 31 December 2025.
| Segment / category | % of revenue | What it is |
|---|---|---|
| Obesity and Diabetes care (reported segment) | 93.7% — DKK 289,456m | The core business. Grew 7% as reported and 10% at constant exchange rates in FY2025 |
| — GLP-1 diabetes (Ozempic, Rybelsus, Victoza) | 49.2% — DKK 152,202m | Ozempic alone was DKK 127,089m, up 10% at constant rates. Rybelsus fell 2% and Victoza, now genericised, fell 43% |
| — Obesity care (Wegovy, Saxenda) | 26.6% — DKK 82,347m | Wegovy was DKK 79,106m, up 41% at constant rates, and is the growth engine. Saxenda, the older liraglutide product, halved |
| — Insulin and other diabetes care | 17.8% — DKK 54,907m | The legacy franchise that built the company. Total insulin sales of DKK 53,137m declined 1% at constant rates |
| Rare disease (reported segment) | 6.3% — DKK 19,608m | Rare blood disorders including haemophilia were DKK 11,955m and rare endocrine disorders including growth hormone were DKK 5,959m, the latter up 24% at constant rates |
By geography, US Operations were DKK 173,166m or 56.0% of FY2025 sales, growing 8% at constant exchange rates, and International Operations were DKK 135,898m or 44.0%, growing 14%. Within International, EUCAN was DKK 66,091m, Emerging Markets DKK 30,436m, APAC DKK 20,713m and Region China DKK 18,658m.
4. Business Model and Moat
How it makes money. Novo Nordisk manufactures and sells branded peptide and biologic therapeutics in roughly 170 countries. Revenue is recognised at list price less an unusually large gross-to-net adjustment: in the United States, rebates to pharmacy benefit managers, Medicaid and the 340B programme are so material that a single provision revision can move a quarter's reported sales by tens of billions of kroner. That is exactly what happened in Q1 2026, when a USD 4.2bn 340B rebate-provision reversal flattered reported sales by roughly DKK 26.8bn.
What the moat rests on. The first pillar is manufacturing. Sterile peptide API synthesis and aseptic fill-finish at GLP-1 scale is a genuinely hard industrial problem with lead times measured in years, which is why Novo spent DKK 60,140m of capital expenditure in FY2025 and why it paid roughly $11bn for three Catalent fill-finish sites rather than building them. The second is intellectual property: the company has filed approximately 320 US patent applications around semaglutide, with the core composition-of-matter patent running to 5 December 2031 in the US after term adjustment, and follow-on formulation and use patents potentially extending exclusivity further. The third is a century of accumulated regulatory and clinical infrastructure in metabolic disease, which is what allows a single molecule to be developed across diabetes, obesity, cardiovascular outcomes, MASH and, less successfully, Alzheimer's.
What it costs to defend. Research and development expense was DKK 52,039m in FY2025, 16.8% of sales, up from DKK 48,062m in FY2024 and DKK 32,443m in FY2023. That spending has produced both the oral semaglutide franchise and the two clinical failures described in Section 2.
5. Financial Health
All figures below are taken from Novo Nordisk's audited annual reports and Form 20-F filings, and have been re-derived independently from the SEC XBRL company facts dataset. Per-share figures are stated on the post-split basis following the two-for-one share split of September 2023.
| Fiscal Year | Revenue (DKK m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| FY2021 | DKK 140,800m | +10.9% | DKK 10.37 | DKK 10.67 | DKK 5.20 | DKK 26,645m |
| FY2022 | DKK 176,954m | +25.7% | DKK 12.22 | DKK 12.62 | DKK 6.20 | DKK 25,784m |
| FY2023 | DKK 232,261m | +31.3% | DKK 18.62 | DKK 19.18 | DKK 9.40 | DKK 27,006m |
| FY2024 | DKK 290,403m | +25.0% | DKK 22.63 | DKK 24.77 | DKK 11.40 | DKK 102,787m |
| FY2025 | DKK 309,064m | +6.4% | DKK 23.03 | DKK 26.17 | DKK 11.70 | DKK 130,958m |
GAAP EPS is IFRS diluted earnings per B share as reported. Adjusted EPS is Novo Nordisk's own non-IFRS adjusted diluted earnings per share, which excludes restructuring and impairment one-offs. Dividend per share is the total interim plus final dividend for the financial year, restated to the post-2023-split basis. Long-term debt is total borrowings at year end per the balance sheet; the step-up from FY2023 to FY2025 reflects the Eurobond issuance used to fund the Catalent fill-finish site acquisition, with EUR 10bn issued during 2025 alone.
| Quarter / Half | Revenue (DKK m) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q2 2026 (reported 4 Aug 2026) | DKK 78,488m | DKK 4.75†‡ | DKK 4.75‡ |
| Q1 2026 (reported 6 May 2026) | DKK 96,823m | DKK 10.91† | DKK 10.91 |
| Q4 2025 (reported 3 Feb 2026) | DKK 79,144m | DKK 6.04† | DKK 6.04 |
| Q3 2025 (reported 5 Nov 2025) | DKK 74,976m‡ | DKK 4.50†‡ | DKK 4.50‡ |
| Q2 2025 (reported 6 Aug 2025) | DKK 76,857m‡ | DKK 5.96†‡ | DKK 5.96‡ |
| FY2025 total | DKK 309,064m | DKK 26.17 | DKK 23.03 |
† Novo Nordisk does not publish a separate adjusted diluted EPS for each individual quarter, only for the full year, so the reported IFRS diluted EPS is repeated in the Adjusted EPS column for quarterly periods. ‡ Derived by subtracting consecutive cumulative reported periods, because Novo Nordisk reports on a cumulative year-to-date basis rather than as discrete quarters.
Two distortions matter when reading that quarterly table. Q1 2026 reported sales of DKK 96,823m include a USD 4.2bn 340B rebate-provision reversal worth roughly DKK 26.8bn; on an adjusted basis excluding it, Q1 2026 sales were DKK 70,063m, down 4% at constant exchange rates. Q2 2026 reported operating profit of DKK 27,061m includes a DKK 6.3bn non-cash impairment, of which DKK 4.0bn relates to monlunabant; adjusted operating profit was DKK 33,389m, up 11% at constant rates.
Cash flow and balance sheet, FY2025. Net cash generated from operating activities was DKK 119,102m, down 2% on FY2024. Capital expenditure on property, plant and equipment was DKK 60,140m and capital expenditure on intangibles a further DKK 29,973m, the latter driven mainly by the Akero Therapeutics acquisition. Depreciation, amortisation and impairment losses added back in the cash flow statement were DKK 21,982m. Free cash flow on the standard definition of operating cash flow less property, plant and equipment capital expenditure was DKK 58,962m; on Novo Nordisk's own definition, which also deducts intangible capital expenditure, it was DKK 28,295m against negative DKK 14,707m in FY2024. Cash and cash equivalents at year end were DKK 26,464m with a further DKK 498m of current financial assets at fair value through profit or loss. Total borrowings were DKK 130,958m. Total assets were DKK 542,902m and total equity DKK 194,047m, an equity ratio of 35.7%. Net financial items were a gain of DKK 2,882m against a loss of DKK 1,148m in FY2024, driven by US dollar hedging gains partly offset by the Catalent financing interest cost.
6. Valuation Metrics
Raw metrics, August 2026. Not opinions on whether the stock is cheap or expensive.
Multiples below are computed in Danish kroner from a B-share reference price of DKK 294.30, the price at which restricted shares vested to directors and executives on 5 August 2026 as disclosed in the managers' transactions announcement. Dollar equivalents use the implied rate of approximately DKK 6.6 per US dollar.
| Metric | Value |
|---|---|
| Market cap | Approximately DKK 1,309bn, equivalent to roughly $197bn (DKK 294.30 applied to approximately 4,448m shares, being FY2025 net profit of DKK 102,434m divided by diluted EPS of DKK 23.03) |
| Trailing P/E (GAAP) | Approximately 12.8x (DKK 294.30 divided by FY2025 IFRS diluted EPS of DKK 23.03). On Novo Nordisk's own FY2025 adjusted diluted EPS of DKK 26.17 the multiple is approximately 11.2x, and on trailing-twelve-month diluted EPS of about DKK 26.20 to Q2 2026 it is also approximately 11.2x, though that trailing figure is flattered by the Q1 2026 340B rebate reversal |
| P/E (forward) | Approximately 13.3x (data-provider estimate, early August 2026; Novo Nordisk guides to sales and operating profit growth ranges rather than an EPS forecast, so this is a third-party calculation) |
| P/S (TTM) | Approximately 4.0x (market cap ~DKK 1,309bn divided by trailing-twelve-month sales of DKK 329,431m, being Q3 2025 DKK 74,976m + Q4 2025 DKK 79,144m + Q1 2026 DKK 96,823m + Q2 2026 DKK 78,488m; note the Q1 2026 component includes the 340B reversal) |
| Enterprise value | Approximately DKK 1,413bn, equivalent to roughly $214bn (market cap ~DKK 1,309bn + total borrowings DKK 130,958m − cash and cash equivalents DKK 26,464m and current financial assets at fair value DKK 498m, all per the FY2025 balance sheet) |
| EV/EBITDA (TTM) | Approximately 9.4x (enterprise value ~DKK 1,413bn divided by FY2025 EBITDA of DKK 149,640m; EBITDA = operating profit DKK 127,658m + depreciation, amortisation and impairment losses of DKK 21,982m taken from the cash flow statement, which is the wider total including impairments rather than the narrower depreciation-and-amortisation-only figure) |
| P/FCF | Approximately 22.2x (market cap ~DKK 1,309bn divided by FY2025 free cash flow of DKK 58,962m; FCF = operating cash flow DKK 119,102m − property, plant and equipment capital expenditure DKK 60,140m). On Novo Nordisk's own free cash flow definition of DKK 28,295m, which also deducts DKK 29,973m of intangible capital expenditure, the multiple is approximately 46x |
| 52-week high | $64.16 on the NVO ADR |
| 52-week low | $35.12 on the NVO ADR. The ADR last traded around $44.53 on 5 August 2026 |
| Short interest (% of float) | Approximately 0.79% of float on the NVO ADR, roughly 26.7m shares short, about 1.87 times average daily volume (Fintel, early August 2026; the exact settlement date is not separately disclosed by that source) |
| Days to cover | Approximately 1.2 days |
| Dividend yield | Approximately 4.0% (FY2025 total declared dividend of DKK 11.70 per share against the DKK 294.30 reference price; the FY2025 payout ratio was 50.7%) |
7. What Are They Building
Oral semaglutide, the format change. The Wegovy pill at 25mg was approved by the FDA on 22 December 2025 as the first oral GLP-1 for obesity and launched in the US on 5 January 2026. By 17 July 2026 it had exceeded five million US prescriptions and 265,000 weekly scripts. EMA approval followed in July 2026 on the OASIS 4 data showing mean weight loss up to 16.6%, with UK and UAE launches in June and July 2026 and broader EU rollout planned for the second half of the year. Separately, Wegovy HD at 7.2mg was approved by the FDA in March 2026 on STEP UP data showing 20.7% mean weight loss, launched in the US on 7 April 2026, and received EU approval in July 2026.
The next-generation obesity pipeline. CagriSema, the combination of cagrilintide and semaglutide, has been submitted to the FDA for weight management on the REDEFINE programme covering roughly 4,600 patients, with a decision expected around the turn of 2026 and 2027; the REIMAGINE 2 and 3 phase 3 trials in diabetes completed successfully. Amycretin, also known as zenagamtide, entered phase 3 in both subcutaneous and oral formulations through the AMAZE programme initiated in Q1 2026.
Beyond metabolic disease. Mim8, or denecimig, was submitted for approval in both the US and EU in 2025 with decisions expected during 2026, and would be the company's first major haemophilia launch in years. The Akero Therapeutics acquisition brings efimosfermin, a phase 3 FGF21 analogue in MASH, and the Omeros deal adds zaltenibart, a MASP-3 inhibitor for rare blood disorders. Two cardiovascular outcomes trials of ziltivekimab, HERMES in heart failure and ARTEMIS post-myocardial-infarction, continue after the ZEUS miss and are expected to read out in the first half of 2027.
The industrial programme. Capital expenditure guidance of roughly DKK 55bn for 2026 follows DKK 60,140m in FY2025, funding active pharmaceutical ingredient and fill-finish capacity at Kalundborg in Denmark, Clayton in North Carolina, and the three former Catalent sites at Anagni, Brussels and Bloomington, which begin contributing capacity from 2026 onwards.
8. Competitive Landscape
| Peer | Market cap (August 2026) | Key 2025 metric |
|---|---|---|
| Eli Lilly (NYSE: LLY) | Approximately $1.06 trillion | Mounjaro and Zepbound generated $36.5bn of combined FY2025 sales, 56% of Lilly's revenue. In Q2 2026 Mounjaro alone was $9.9bn, up 91% year on year, and Lilly raised FY2026 revenue guidance to $85bn to $87bn |
| Roche (SIX: ROG) | Approximately $367bn | FY2025 group sales of CHF 61.5bn, up 7% at constant rates, with the Pharmaceuticals division at CHF 47.7bn. Roche is building an incretin portfolio through the Carmot acquisition |
| AstraZeneca (LSE: AZN) | — | FY2025 total revenue of $58.7bn, up 9%. Competes in cardiometabolic disease and has an oral GLP-1 candidate in development |
| Pfizer (NYSE: PFE) | Approximately $147bn | FY2025 revenue of $62.6bn, down 2% as reported. Acquired Metsera in late 2025 after outbidding Novo Nordisk, buying its way into the obesity category |
| Sanofi (EPA: SAN) | Approximately $103bn | FY2025 net sales of EUR 43.6bn, up 9.9% at constant rates, with EPS of EUR 7.83. Competes primarily in insulin and immunology rather than incretins |
Peer market capitalisations are point-in-time figures from market data trackers rather than company filings, and were re-checked in the first week of August 2026. Treat them as approximate.
9. Insider Activity
Novo Nordisk discloses insider dealing as managers' transactions under Article 19 of the EU Market Abuse Regulation rather than through SEC Form 4. Chief Executive Maziar "Mike" Doustdar, who took the role on 7 August 2025, appears in the most recent disclosure alongside the rest of the executive management team and several directors. Every transaction in the 6 August 2026 announcement was an automatic vesting under the Novo Nordisk 100th Anniversary Shares restricted-share programme, executed outside a trading venue at DKK 294.30 per share on 5 August 2026. These are plan vestings rather than discretionary open-market decisions, and no open-market purchases or sales by insiders were identified in the period immediately preceding this report.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Maziar Mike Doustdar (President and CEO) | 05 Aug 2026 | Vesting | 74 | DKK 294.30 | DKK 21,778 | 100th Anniversary Restricted Shares programme |
| Karsten Munk Knudsen (EVP and CFO) | 05 Aug 2026 | Vesting | 74 | DKK 294.30 | DKK 21,778 | 100th Anniversary Restricted Shares programme |
| Martin Holst Lange (EVP, R&D and CSO) | 05 Aug 2026 | Vesting | 74 | DKK 294.30 | DKK 21,778 | 100th Anniversary Restricted Shares programme |
| Emil Kongshøj Larsen (EVP, International Operations) | 05 Aug 2026 | Vesting | 74 | DKK 294.30 | DKK 21,778 | 100th Anniversary Restricted Shares programme |
| Kasper Bødker Mejlvang (EVP, Global Manufacturing and Supply) | 05 Aug 2026 | Vesting | 74 | DKK 294.30 | DKK 21,778 | 100th Anniversary Restricted Shares programme |
| Désirée Jantzen Asgreen (Board member) | 05 Aug 2026 | Vesting | 74 | DKK 294.30 | DKK 21,778 | 100th Anniversary Restricted Shares programme |
10. Key Risks
- Competitive share loss to Eli Lilly: Novo Nordisk's global diabetes value market share fell 3.6 percentage points to 30.1% in the year to November 2025, while Lilly's Mounjaro grew 91% year on year in Q2 2026. In a two-player category, share loss compounds because it also erodes formulary negotiating position.
- Structural US price reset: the most-favoured-nation agreement announced in November 2025 takes Wegovy and Ozempic to roughly $350 a month through TrumpRx and $245 a month for Medicare. This is a permanent change to realised revenue per prescription in the company's largest market, which was 56.0% of FY2025 sales.
- Patent expiry outside the United States: the semaglutide compound patent has lapsed in Canada, where generics from four manufacturers were approved between January and April 2026, and similar exposure exists in India, China, Brazil and Turkey. Each generic entry is a step-change reduction in that market's revenue, not a gradual erosion.
- Clinical failure risk in a concentrated pipeline: the EVOKE Alzheimer's trials failed and the ZEUS ziltivekimab trial missed its primary endpoint on 31 July 2026, triggering an 8.8% single-day share fall and a DKK 6.3bn impairment. Because so much of the pipeline extends a single molecule class, correlated failure is a real exposure.
- Leverage and capital intensity: total borrowings rose from DKK 27,006m at end-FY2023 to DKK 130,958m at end-FY2025 to fund the Catalent fill-finish acquisition, while annual capital expenditure runs near DKK 55bn to DKK 60bn. If volume growth undershoots, that capacity becomes a fixed-cost drag rather than a moat.
- Compounded and unlicensed semaglutide: despite the expiry of the FDA compounding grace period in May 2025, unapproved compounded product persists. Novo Nordisk won a Dutch court injunction against a compounded semaglutide nasal spray on 5 August 2026 and continues litigation in the US and EU, but enforcement is jurisdiction-by-jurisdiction and slow.
- Governance and leadership disruption: a new chief executive from August 2025, a wholesale board refresh at an extraordinary general meeting on 14 November 2025 explicitly framed around the Foundation's controlling position, and a 9,000-role restructuring together create meaningful execution risk that will not resolve for several quarters.
- Currency exposure: a 5% move in the US dollar alone shifts adjusted operating profit by roughly DKK 4.3bn a year. Reported DKK growth has already been running several percentage points below constant-currency growth, and that gap is outside management's control.
11. Recent Developments
- 05 Jan 2026 — Wegovy pill launches in the United States. Oral semaglutide 25mg became the first oral GLP-1 available for weight management, following FDA approval on 22 December 2025.
- 03 Feb 2026 — FY2025 results and a downbeat first guide for 2026. Net sales of DKK 309,064m grew 10% at constant rates and operating profit of DKK 127,658m grew 6%, with diluted EPS of DKK 23.03. Management introduced a new adjusted sales and adjusted operating profit framework and guided FY2026 growth of minus 5% to minus 13% at constant rates.
- 26 Mar 2026 — Annual General Meeting. Shareholders approved the final FY2025 dividend of DKK 7.95 per share, taking the full-year total to DKK 11.70, and a DKK 15bn share repurchase programme for 2026.
- 07 Apr 2026 — Wegovy HD launches in the United States. The 7.2mg high-dose pen reached the US market following March 2026 FDA approval on STEP UP data showing 20.7% mean weight loss.
- 06 May 2026 — Q1 2026 results and a first guidance raise. Reported net sales of DKK 96,823m rose 32% at constant rates, boosted by a USD 4.2bn 340B rebate-provision reversal; adjusted sales fell 4%. Full-year guidance improved to minus 4% to minus 12%.
- 21 Jul 2026 — Novo Nordisk sues Eli Lilly over GLP-1 advertising. The company filed a false-advertising action targeting what it described as multiple misleading national comparison campaigns.
- 31 Jul 2026 — ZEUS phase 3 trial misses its primary endpoint. Ziltivekimab failed to reduce major adverse cardiovascular events in patients with atherosclerotic disease, chronic kidney disease and inflammation, with a hazard ratio of 0.99. The shares fell 8.8% intraday and an impairment followed.
- 04 Aug 2026 — Q2 2026 results and a second guidance raise. Net sales of DKK 78,488m and adjusted operating profit of DKK 33,389m, up 11% at constant rates, against reported operating profit of DKK 27,061m after a DKK 6.3bn impairment. FY2026 guidance was lifted again to 0% to minus 6% at constant rates.
- 05 Aug 2026 — Dutch court injunction against compounded semaglutide. Novo Nordisk secured an injunction blocking an unapproved compounded semaglutide nasal spray, part of a broader enforcement campaign across multiple jurisdictions.
- 06 Aug 2026 — Managers' transactions disclosed. The chief executive, chief financial officer, the rest of executive management and several directors each received 74 restricted shares vesting at DKK 294.30 under the 100th Anniversary Shares programme.
12. Key Dates to Watch
- 14 Aug 2026 — ex-dividend date for the 2026 interim dividend on the Nasdaq Copenhagen B shares.
- 17 Aug 2026 — ex-dividend date for the NYSE ADRs, and record date for both B shares and ADRs.
- 18 Aug 2026 — interim dividend payment date for B shares.
- 25 Aug 2026 — interim dividend payment date for ADR holders.
- 21 Sep 2026 — Capital Markets Day, at which management is expected to unveil new Strategic Aspirations. The first full strategic reset under the new chief executive and board.
- 04 Nov 2026 — Q3 2026 results, and the first quarter to include a full period of EU oral semaglutide rollout.
- Expected Dec 2026 — FDA decision on CagriSema for weight management is anticipated around the turn of 2026 and 2027, the single largest binary event in the pipeline.
- 03 Feb 2027 — FY2026 results and the Annual Report 2026.
- Expected Jun 2027 — readouts from the HERMES and ARTEMIS cardiovascular outcomes trials of ziltivekimab, both guided to the first half of 2027.
Track scheduled macro and policy events that move pharmaceutical valuations on our Economic Calendar, and discuss this research with other members in the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 4 August 2026
Stryker Corporation is one of the world's largest pure-play medical technology companies, selling surgical implants, power tools, endoscopy platforms, hospital equipment and the Mako family of surgical robots into roughly 61 countries. Fiscal 2025 was its strongest year in a decade: net sales of $25,116m, organic growth of 10.3% and a second consecutive year of 100 basis points of adjusted operating margin expansion. Fiscal 2026 has been far more eventful. A material cybersecurity incident in March knocked first-quarter adjusted earnings down 8.5% and drove the shares to a 52-week low of $281.00 in May, before a strong second quarter and the full United States launch of the handheld Mako RPS robot restored momentum. This report sets out what Stryker actually reports, what it is building, and what the numbers look like at today's price. It contains no analyst opinions, ratings or price targets.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Stryker Corporation |
| Ticker / Exchange | SYK, New York Stock Exchange |
| Share price | $341.20 (last trade 3 Aug 2026; prior settled close $325.70 on 31 Jul 2026) |
| Market cap | $130.80bn (383.36m shares outstanding at $341.20, 3 Aug 2026) |
| Revenue (FY2025, year ended 31 Dec 2025) | $25,116m, up 11.2% year on year (organic +10.3%) |
| Net earnings (FY2025) | Approximately $3.24bn (GAAP diluted EPS $8.40 on roughly 386m weighted diluted shares) |
| Adjusted diluted EPS (FY2025) | $13.63, up 11.8% |
| CEO / Leadership | Kevin A. Lobo, Chair and Chief Executive Officer (CEO since October 2012). Spencer Stiles became President and Chief Operating Officer on 1 Jan 2026; Preston W. Wells is Vice President, Chief Financial Officer |
| Employees | Approximately 56,000 globally at 31 Dec 2025, of which roughly 28,000 in the United States |
| Headquarters | 1941 Stryker Way, Portage, Michigan, United States |
| Founded / incorporated | Founded 1941 by Dr Homer H. Stryker; incorporated in Michigan in 1946 |
| Reportable segments | Two: MedSurg and Neurotechnology; Orthopaedics |
| Dividend | $0.88 per quarter, $3.52 annualised, a yield of approximately 1.03% at $341.20 |
| Sector | Healthcare, medical devices (SEC SIC 3841, Surgical and Medical Instruments) |
You can pull up an interactive price chart for Stryker and its peers on the ChartsView Live Charts page.
2. The Bull and Bear Case
Bull Case
- Compounding organic growth at scale: Stryker grew organic sales 10.3% in fiscal 2025 on a $25bn base, and management narrowed fiscal 2026 organic growth guidance to 8.3% to 9.3% on 30 July 2026 after a 9.0% organic second quarter. Very few medical technology companies of this size sustain high single-digit organic growth.
- Mako is now a two-product robotics franchise: more than 2 million robotic procedures have been performed across Mako Total Knee, Total Hip and Partial Knee, with the platform available in over 45 countries. The handheld Mako RPS reached full United States market release on 16 July 2026, opening ambulatory surgery centres and manual-technique surgeons that the capital-heavy Mako arm cannot economically reach. Record Mako installations were reported in the second quarter of 2026.
- Margin expansion is being delivered, not promised: adjusted operating margin rose 100 basis points in each of fiscal 2024 and fiscal 2025 to 26.3%, and expanded a further 170 basis points to 27.4% in the second quarter of 2026 despite absorbing cyber-recovery costs.
- Cash generation funds the deal machine internally: operating cash flow rose from $3,711m in fiscal 2023 to $5,044m in fiscal 2025 against capital expenditure of only $761m, leaving $4,283m of free cash flow. That funded the $4,810m Inari acquisition, the Amplitude Vascular Systems deal and a 4.8% dividend increase without equity issuance.
Bear Case
- The valuation leaves no margin for error: at $341.20 the shares trade on roughly 22.7 times management's own fiscal 2026 adjusted EPS guidance midpoint, against 13.5 times for Medtronic, 14.1 times for Boston Scientific and 10.8 times for Zimmer Biomet. The 6.4% single-day fall on 31 July 2026, after an adjusted earnings beat, shows how little tolerance that premium carries.
- The cyber incident proved the operating model is fragile: the 11 March 2026 disruption to Stryker's Microsoft environment hit manufacturing, ordering and distribution, cut first-quarter adjusted EPS by 8.5% year on year and compressed adjusted operating margin by 180 basis points. Remediation cost, litigation and regulatory exposure are all still open.
- Reported earnings quality is flattered by one-offs: fiscal 2025 GAAP diluted EPS of $8.40 included a $660m discrete tax benefit worth $1.71 per share, and second-quarter 2026 GAAP EPS of $3.30 included a $158m tariff reversal worth $0.34 per share. The headline trailing price to earnings multiple is helped by both.
- Insider selling is one-directional and large: approximately $444m of stock was sold by insiders over the twelve months to August 2026 with zero open-market purchases, 98.7% of it by director and founding-family heir Ronda E. Stryker, and only one transaction in the entire period was disclosed as a Rule 10b5-1 plan sale.
3. Business Segments
Stryker reports two segments. The old "Orthopaedics and Spine" label was dropped after the United States spinal implants business was sold to VB Spine on 1 April 2025.
| Segment | % of revenue | What it is |
|---|---|---|
| MedSurg and Neurotechnology | 62% ($15,647m of $25,116m, FY2025) | Surgical power tools, navigation and operating-room safety systems, endoscopic and visualisation platforms, hospital beds, stretchers, emergency medical services and defibrillation equipment, clinical communication and AI-assisted virtual care software, plus minimally invasive devices for stroke and venous thromboembolism and products for brain and skull-base surgery. |
| Orthopaedics | 38% ($9,469m of $25,116m, FY2025) | Implants for total joint replacement of the hip, knee, shoulder and ankle and for trauma and extremities surgery, together with Mako robotic-arm-assisted and handheld robotic technology and the associated orthopaedic instrumentation. |
Underneath the two segments, Stryker discloses the following business lines for fiscal 2025.
| Business line | FY2025 revenue | Parent segment |
|---|---|---|
| Medical | $4,204m | MedSurg and Neurotechnology |
| Endoscopy | $3,807m | MedSurg and Neurotechnology |
| Instruments | $3,183m | MedSurg and Neurotechnology |
| Neuro Cranial | $2,485m | MedSurg and Neurotechnology |
| Vascular | $1,968m | MedSurg and Neurotechnology |
| Trauma and Extremities | $3,948m | Orthopaedics |
| Knees | $2,656m | Orthopaedics |
| Hips | $1,865m | Orthopaedics |
| Other Orthopaedics | $815m | Orthopaedics |
| Spinal Implants | $185m (down from $707m in FY2024) | Orthopaedics, divested |
Geographically, the United States generated $19,006m of fiscal 2025 revenue, up 12.2%, and international markets $6,110m, up 8.1%. The "Vascular" line was renamed from Neurovascular during 2025 following the Inari Medical acquisition. In the first quarter of 2026 Stryker created a new "Ortho Tech" business line combining orthopaedic instruments and other orthopaedics, and moved Neuro Cranial and spine enabling technologies into Instruments; all prior periods were restated for that reallocation, but the two reportable segments were unchanged.
4. Business Model and Moat
How it makes money. Stryker sells a mixture of high-volume consumables and implants and lower-volume, higher-ticket capital equipment. Implants such as knees, hips and trauma plates are consumed one per procedure and are effectively an annuity tied to surgical volumes. Capital equipment such as Mako robots, LIFEPAK defibrillators, hospital beds and 4K camera platforms is bought in lumps out of hospital capital budgets, which is why the fourth quarter is structurally the largest: fourth-quarter 2025 revenue of $7,171m ran roughly 19% above the average of the first three quarters.
The razor-and-blade mechanic in robotics. A Mako placement is the razor. Once a hospital installs one, the surgeons trained on it use Stryker knee and hip implants, Stryker instruments and Stryker software, and the switching cost of retraining a surgical team is high. This is why installed base matters more than robot revenue: over 1 million Mako Total Knee procedures have now been performed. The Mako RPS handheld system extends the same mechanic downmarket to ambulatory surgery centres that will never buy a full robotic arm.
Where the moat comes from. Three things. First, surgeon habit and training, which is the single stickiest asset in orthopaedics. Second, regulatory and clinical evidence barriers, with roughly 5,600 United States patents and 9,000 non-United States patents at 31 December 2025 and a 510(k) pathway that rewards incumbents with predicate devices. Third, hospital contracting scale, where breadth across the operating room, the ward and the ambulance lets Stryker bundle in a way that single-category competitors cannot.
Where it is thinner than it looks. Stryker spent $1,623m on research, development and engineering in fiscal 2025, which is 6.5% of sales, a lower intensity than most large-cap technology businesses and a reminder that a meaningful share of the growth is bought rather than invented. Three acquisitions closed in eighteen months. The newly created Peripheral Vascular reporting unit is carried with, in the company's own words in the FY2025 10-K, a fair value that "was not expected to exceed its carrying value by a significant amount".
5. Financial Health
All figures below are taken from Stryker's fiscal year earnings press releases, Forms 10-K and 10-Q, and SEC XBRL company facts. Fiscal years end 31 December.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| FY2021 | 17,108 | +19.2% | $5.21 | $9.09 | $2.585 | $12,472m |
| FY2022 | 18,449 | +7.8% | $6.17 | $9.34 | $2.835 | $11,857m |
| FY2023 | 20,498 | +11.1% | $8.25 | $10.60 | $3.050 | $10,901m |
| FY2024 | 22,595 | +10.2% | $7.76 † | $12.19 | $3.240 | $12,188m |
| FY2025 | 25,116 | +11.2% | $8.40 ‡ | $13.63 | $3.400 | $14,859m |
† Fiscal 2024 GAAP diluted EPS was depressed by $977m of goodwill and other impairments relating to the Spine business, worth approximately $2.21 per share.
‡ Fiscal 2025 GAAP diluted EPS was inflated by a $660m discrete tax benefit worth approximately $1.71 per share. The GAAP effective tax rate was 28.1% against an adjusted rate of 15.1%.
Long-term debt is the non-current balance-sheet figure taken from the SEC XBRL tag LongTermDebtNoncurrent. Total debt including the current portion was $15,859m at 31 December 2025 and $14,942m at 30 June 2026.
| Quarter / Half | Revenue ($m) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q2 2026 (ended 30 Jun 2026) | 6,589 | $3.69 | $3.30 |
| Q1 2026 (ended 31 Mar 2026) | 6,020 | $2.60 | $1.93 |
| Q4 2025 (ended 31 Dec 2025) | 7,171 | $4.47 | $2.20 |
| Q3 2025 (ended 30 Sep 2025) | 6,057 | $3.19 | $2.22 |
| Q2 2025 (ended 30 Jun 2025) | 6,022 | $3.13 | $2.29 |
| FY2025 total | 25,116 | $13.63 | $8.40 |
Cash flow and balance sheet. Fiscal 2025 net cash provided by operating activities was $5,044m against $4,242m in fiscal 2024. Purchases of property, plant and equipment were $761m, giving free cash flow of $4,283m. Depreciation and amortisation was $1,570m on the total basis used in the segment note and the XBRL tag DepreciationDepletionAndAmortization; the narrower cash flow statement add-back was $1,193m. Earnings from operations were $4,889m, or 19.5% of sales, with adjusted operating income of $6,603m, or 26.3%.
At 30 June 2026, the most recent reported balance sheet, Stryker held cash and cash equivalents of $3,391m plus marketable securities of $85m, against long-term debt excluding current maturities of $14,192m and a current portion of debt of $750m. Total assets were $47,930m and shareholders' equity $23,988m. First-half 2026 operating cash flow was $1,842m against $1,361m in the first half of 2025, with capital expenditure of $368m, acquisitions net of cash of $459m, dividends paid of $674m and $750m of net debt repayment.
6. Valuation Metrics
Raw metrics, August 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | $130.80bn (383,360,762 shares at $341.20, 3 Aug 2026) |
| Enterprise value | Approximately $142.3bn (market cap $130.80bn plus total debt $14,942m less cash $3,391m and marketable securities $85m, per the 30 Jun 2026 balance sheet) |
| Trailing P/E (GAAP) | 35.4x on trailing twelve-month GAAP diluted EPS of $9.65 ($2.22 + $2.20 + $1.93 + $3.30). On trailing adjusted EPS of $13.95 the multiple is 24.5x. Note the GAAP figure is flattered by a $660m fiscal 2025 tax benefit and a $158m tariff reversal in Q2 2026 |
| P/E (forward) | 22.7x on management's own FY2026 adjusted diluted EPS guidance of $14.95 to $15.10, narrowed on 30 Jul 2026 (midpoint $15.025). Range 22.6x to 22.8x. This is company guidance, not an analyst estimate |
| P/S (TTM) | 5.06x on trailing twelve-month revenue of $25,837m ($6,057m + $7,171m + $6,020m + $6,589m) |
| EV/EBITDA (TTM) | Approximately 22.0x (enterprise value $142.27bn divided by EBITDA of $6,459m; EBITDA = FY2025 operating income $4,889m plus depreciation and amortisation $1,570m) |
| P/FCF | Approximately 30.5x (market cap $130.80bn divided by free cash flow $4,283m; FCF = FY2025 operating cash flow $5,044m less capital expenditure $761m) |
| 52-week high | $396.86, set 4 Sep 2025 |
| 52-week low | $281.00, set 11 May 2026, two months after the cybersecurity incident |
| Short interest (% of float) | 1.91% (7,029,895 shares short against a float of 347.79m, settlement date 15 Jul 2026). Short interest has risen from 4.61m shares in September 2025 |
| Days to cover | 2.55 |
| Price/book | 5.45x on shareholders' equity of $23,988m at 30 Jun 2026 |
| Dividend yield | Approximately 1.03% ($0.88 quarterly, $3.52 annualised) |
7. What Are They Building
Stryker spent $1,623m on research, development and engineering in fiscal 2025 on a reported basis, or $1,567m adjusted, equal to 6.5% and 6.2% of sales respectively. First-half 2026 spending was $847m, up 4.3% year on year, of which $434m fell in the second quarter.
Mako robotics is the centre of gravity. Mako SmartRobotics is now available in more than 45 countries, with over 1 million robotic Mako Total Knee procedures and more than 2 million total robotic procedures performed across knee, hip and partial knee. The Mako 4 platform, introduced in 2025 and built around the Q-Guidance advanced guidance system, is the generational hardware and software refresh intended to carry new applications across subspecialties. Mako Total Hip with Advanced Primary and Revision reached full market release in the third quarter of 2025, the first robotically enabled revision hip arthroplasty on the market and the first application built on Mako 4. Mako Shoulder, which combines Tornier implants with Blueprint planning software and haptic guidance, moved from limited release through 2025 towards full United States commercial launch.
Mako RPS is the strategically important one. RPS is Stryker's first handheld robotic platform, cleared by the FDA under 510(k) in August 2025, with first cases in January 2026, limited market release on 9 February 2026 and full United States market launch on 16 July 2026. It is currently cleared only for total knee arthroplasty. Its purpose is to reach ambulatory surgery centres and surgeons who still operate manually and have resisted the capital cost and footprint of the Mako arm. In other words, it attacks a market that Stryker's own flagship robot cannot serve, and it defends a knee franchise that generated $2,656m of revenue in fiscal 2025. Record Mako installations were reported in the second quarter of 2026, alongside an elevated capital backlog.
Digital surgery and the connected hospital. The Vocera clinical communication and AI-assisted virtual care platform is now a named product category within the Medical division, with the Vocera Sync Badge launched in 2025 as a hands-free clinician endpoint delivering real-time alerts. The Connected OR IP BRAVoE integration portfolio, also launched in 2025, extends the iSuite integrated operating room.
New product launches across the portfolio. In Instruments, Steri-Shield 8, a lighter operating-room personal protection system. In Endoscopy, continued rollout of the 4K 1788 camera platform across urology, neurology, ENT and arthroscopy. In Medical, the global launch of the LIFEPAK 35 monitor and defibrillator with the Glasgow 30.4 algorithm and cprINSIGHT. In Vascular, the Broadway System for large-bore stroke procedures and an accelerated launch of the Surpass Elite flow-diverting stent, alongside the Inari FlowTriever and ClotTriever mechanical thrombectomy franchises. In Neuro Cranial, OptaBlate BVN radiofrequency ablation for vertebrogenic pain. The Amplitude Vascular Systems acquisition completed on 7 May 2026 adds carbon-dioxide-generated pressure-wave intravascular lithotripsy for calcified peripheral arterial disease, putting Stryker directly against the entrenched Shockwave franchise now owned by J&J MedTech.
8. Competitive Landscape
Stryker names its own competitors in its Form 10-K: Zimmer Biomet, Medtronic, J&J MedTech and ConMed Linvatec in instruments; Karl Storz, Olympus, Smith & Nephew, Arthrex and STERIS in endoscopy; Baxter, Zoll and Medline in medical; Medtronic, J&J MedTech, Terumo and Penumbra in vascular and neuro cranial; and Zimmer Biomet, J&J MedTech and Smith & Nephew in orthopaedics and robotics.
| Peer | Market cap (Aug 2026) | Key 2025 metric |
|---|---|---|
| Johnson & Johnson (NYSE: JNJ) | $613.10bn | FY2025 total revenue $94,193m across pharmaceuticals and MedTech; J&J MedTech is only one segment of the group |
| Medtronic plc (NYSE: MDT) | $110.95bn | Revenue of $36,364m for the fiscal year ended 30 Apr 2026 |
| Boston Scientific (NYSE: BSX) | $71.98bn | FY2025 revenue $20,074m |
| Zimmer Biomet (NYSE: ZBH) | $18.76bn | FY2025 revenue $8,232m, the closest direct comparator in hips and knees |
| Smith & Nephew (NYSE: SNN) | $13.51bn | FY2025 revenue $6,164m |
| Globus Medical (NYSE: GMED) | $11.06bn | Trailing twelve-month revenue $3,101m; the nearest listed pure-play in spine and orthopaedic robotics now that Stryker has exited spine |
On the forward multiples described in Section 6, Stryker trades at roughly 22.7 times management-guided fiscal 2026 adjusted earnings against 13.5 times for Medtronic, 14.1 times for Boston Scientific, 14.1 times for Smith & Nephew and 10.8 times for Zimmer Biomet. Stryker's market capitalisation exceeds Zimmer Biomet, Smith & Nephew and Globus Medical combined. Peer revenue figures here are drawn from market-data income statements rather than each company's own filings and should be treated as cross-check grade.
9. Leadership and Insider Activity
Kevin A. Lobo has been Chief Executive Officer since October 2012 and remains Chair and CEO, quoted by name in the second-quarter 2026 earnings release dated 30 July 2026. He relinquished the President title on 1 January 2026 when Spencer Stiles, previously Group President of Orthopaedics, was appointed President and Chief Operating Officer. Dylan Crotty became Group President, Orthopaedics on the same date. Preston W. Wells is Vice President, Chief Financial Officer. William E. Berry Jr retires as Chief Accounting Officer on 1 September 2026 and is succeeded by Emily Baculik.
Across the twelve months to 4 August 2026 there were thirteen reported open-market insider transactions in Stryker stock. Every one was a sale. There were no open-market purchases.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Ronda E. Stryker, Director | 26 May 2026 | Sale | 310,000 | $312.23 | $96,792,668 | No plan disclosed |
| Robert S. Fletcher, VP Chief Legal Officer | 28 May 2026 | Sale | 4,544 | $306.87 | $1,394,409 | Rule 10b5-1 |
| M. Kathryn Fink, VP Chief HR Officer | 11 May 2026 | Sale | 8,720 | $283.69 | $2,473,756 | No plan disclosed |
| Ronda E. Stryker, Director | 05 Feb 2026 | Sale | 250,000 | $363.95 | $90,988,528 | No plan disclosed |
| Ronda E. Stryker, Director | 04 Feb 2026 | Sale | 250,000 | $362.92 | $90,730,740 | No plan disclosed |
| James Andrew Pierce, Group President | 02 Feb 2026 | Sale | 475 | $368.87 | $175,214 | No plan disclosed |
| Preston W. Wells, VP Chief Financial Officer | 20 Nov 2025 | Sale | 165 | $365.88 | $60,370 | No plan disclosed |
| William E. Berry Jr, VP Chief Accounting Officer | 14 Nov 2025 | Sale | 1,953 | $365.49 | $713,801 | No plan disclosed |
| Ronda E. Stryker, Director | 06 Nov 2025 | Sale | 276,173 | $353.28 | $97,565,693 | No plan disclosed |
| Ronda E. Stryker, Director | 05 Nov 2025 | Sale | 243,827 | $356.98 | $87,040,447 | No plan disclosed |
| Viju Menon, Group President | 25 Aug 2025 | Sale | 500 | $390.61 | $195,305 | No plan disclosed |
| Robert S. Fletcher, VP Chief Legal Officer | 20 Aug 2025 | Sale | 1,785 | $393.07 | $701,629 | No plan disclosed |
| Ronda E. Stryker, Director | 06 Aug 2025 | Sale | 200,000 | $376.45 | $75,289,655 | No plan disclosed |
The totals are 1,298,142 shares sold for approximately $444.1m. Ronda E. Stryker, a director and heir of the founding family, accounts for 1,280,000 shares and roughly $438.4m of that, or 98.7%, sold indirectly through a revocable trust in large blocks roughly quarterly. Only the Fletcher sale of 28 May 2026 was explicitly disclosed as a Rule 10b5-1 plan transaction. Chief Executive Kevin Lobo did not sell in the open market during the period.
10. Key Risks
- Cybersecurity (Operational): the 11 March 2026 incident caused a global disruption to Stryker's Microsoft environment, hitting manufacturing, ordering and distribution. It cut first-quarter 2026 adjusted EPS by 8.5% year on year to $2.60 and reduced adjusted operating margin by 180 basis points. A follow-up filing confirmed a malicious file was used, contradicting the company's initial statement. Data-breach litigation, regulatory action and remediation cost all remain live. Third-party claims about the scale of the intrusion are not company-confirmed.
- Tariffs and trade policy (Macro): Stryker guided to a $200m tariff impact in May 2025, revised it to $175m, then declined to forecast 2026 tariffs at all. In the second quarter of 2026 it booked a $158m reversal of 2025 tariffs through gross profit following the February 2026 Supreme Court ruling on IEEPA authority. New Section 232 and 301 duties and retaliatory measures remain unquantified, and management itself will not put a number on them.
- Recalls and product liability (Legal): the accrual for recall-related and legacy product liability matters was $144m at 31 December 2025, covering Rejuvenate and ABG II modular-neck hip stems, certain LFIT Anatomic CoCr V40 femoral heads and legacy Wright hip claims. Recall-related charges ran $58m in 2025, $40m in 2024 and $18m in 2023. Active matters include the patient-fitted TMJ reconstruction prosthesis notification first issued 30 September 2025 and twice expanded, in which a screw penetrated the cranial vault and one serious injury was reported.
- Acquisition and integration risk (Financial): three deals closed in eighteen months, headed by Inari at $4,810m net of cash. The new Peripheral Vascular reporting unit is carried with minimal impairment headroom by the company's own description. The precedent is unhelpful: Stryker wrote off $977m on Spine in fiscal 2024 before selling it. Acquisition and integration costs ran $508m at operating level in fiscal 2025, and second-quarter 2026 United States Vascular sales fell 6.7%.
- Competitive pressure in robotics (Operational): Zimmer Biomet, J&J MedTech and Smith & Nephew compete directly in joints, trauma and robotics, and Globus Medical is a listed pure-play alternative. Mako RPS only reached full United States launch on 16 July 2026 and is cleared solely for total knee arthroplasty. Stryker also granted VB Spine exclusive access to Mako Spine and Copilot as part of the divestiture, ceding a robotics adjacency outright.
- Hospital capital expenditure cycle (Macro): capital equipment sales are structurally concentrated in the fourth quarter and orthopaedic volumes dip in summer. Management flagged an elevated backlog and record Mako installations in the second quarter of 2026, which converts capital-budget timing into concentrated earnings risk if hospital budgets tighten.
- Valuation and expectations (Financial): a premium of 60% to 110% over every listed peer on forward earnings leaves little room for disappointment. The shares fell 6.4% on 31 July 2026 despite an adjusted earnings beat, because revenue came in modestly light and the full-year outlook was narrowed rather than raised.
- Currency (Macro): international sales were $6,110m, or 24% of fiscal 2025 revenue. Currency swung from a 0.5% headwind in fiscal 2025 to a tailwind in 2026, and management's fiscal 2026 guidance explicitly assumes rates hold near current levels, so the guidance carries embedded currency risk.
- Leadership transition (Governance): three senior changes inside nine months, being a new President and Chief Operating Officer, a new Group President of Orthopaedics and a new Chief Accounting Officer from 1 September 2026. Kevin Lobo has been CEO since 2012 and gave up the President title on 1 January 2026, a conventional succession-grooming signal.
- Regulatory compliance cost (Regulatory): Stryker adjusts out medical device regulation costs every year, being $38m in 2025, $58m in 2024 and $96m in 2023, chiefly EU MDR compliance. The 10-K warns FDA enforcement can bring fines, warning letters, product seizures, recalls and import restrictions, and flags the European Union's new collective-redress regime as an emerging litigation vector.
11. Recent Developments
- 30 Oct 2025 — Third-quarter 2025 results. Sales of $6,057m, up 10.3% reported and 9.5% organic, adjusted EPS of $3.19, up 11.1%, and adjusted operating margin up 90 basis points to 25.6%.
- 04 Dec 2025 — Senior leadership succession announced. Spencer Stiles appointed President and Chief Operating Officer effective 1 January 2026, with Dylan Crotty promoted to Group President, Orthopaedics. Kevin Lobo remains Chair and CEO.
- 29 Jan 2026 — Fiscal 2025 results and initial fiscal 2026 outlook. Full-year sales of $25,116m, up 11.2% reported and 10.3% organic, adjusted EPS of $13.63, up 11.8%, and adjusted operating margin up 100 basis points to 26.3% for a second consecutive year. The quarterly dividend was raised 4.8% to $0.88. Initial fiscal 2026 guidance was organic growth of 8.0% to 9.5% and adjusted EPS of $14.90 to $15.10.
- 09 Feb 2026 — Limited market release of Mako RPS. Stryker's first handheld robotic platform entered limited release for total knee arthroplasty, following FDA 510(k) clearance of the console, saw and software in August 2025.
- 11 Mar 2026 — Material cybersecurity incident disclosed. A global disruption to Stryker's Microsoft environment hit manufacturing, ordering and distribution systems. A follow-up filing on 23 March 2026 confirmed an investigation with Palo Alto Networks Unit 42 and that a malicious file had been used but could not spread.
- 13 Apr 2026 — Agreement to acquire Amplitude Vascular Systems. A next-generation intravascular lithotripsy platform for calcified peripheral arterial disease; the transaction completed on 7 May 2026 at an undisclosed price.
- 30 Apr 2026 — First-quarter 2026 results, the cyber-hit quarter. Sales of $6,020m, up only 2.6% reported and 2.4% organic, adjusted EPS down 8.5% to $2.60 and adjusted operating margin down 180 basis points to 21.1%. Management reaffirmed full-year guidance.
- 11 May 2026 — Shares set a 52-week low of $281.00. Roughly two months after the cybersecurity incident, and approximately 29% below the September 2025 high.
- 26 May 2026 — Director Ronda E. Stryker sells 310,000 shares. At an average of $312.23, or approximately $96.8m, her largest single-day disposal of the period and the fifth large block in twelve months.
- 16 Jul 2026 — Full United States market launch of Mako RPS. Expanding the Mako portfolio beyond robotic-arm-assisted surgery into handheld robotics, aimed at ambulatory surgery centres and manual-technique surgeons.
- 30 Jul 2026 — Second-quarter 2026 results. Sales of $6,589m, up 9.4% reported and 9.0% organic, adjusted EPS of $3.69, up 17.9%, reported EPS of $3.30, up 44.1%, and adjusted operating margin up 170 basis points to 27.4%. The results included a $158m reversal of 2025 tariffs. Full-year guidance was narrowed to organic growth of 8.3% to 9.3% and adjusted EPS of $14.95 to $15.10, with record Mako installations and an elevated capital backlog reported.
- 31 Jul 2026 — Shares fall 6.4%. From $348.04 to $325.70 in the session after results, despite the adjusted earnings beat, as investors focused on modestly light revenue and second-half execution risk.
12. Key Dates to Watch
- 01 Sep 2026 — Emily Baculik becomes Vice President, Chief Accounting Officer, succeeding William E. Berry Jr on his retirement.
- Expected late September 2026 — next quarterly dividend declaration and record date. The prior-year cadence was a record date of 30 September with payment on 31 October. Not yet announced by the company.
- Expected late October 2026 — third-quarter 2026 results. Stryker typically announces the date around four weeks ahead; third-quarter 2025 results were released on 30 October 2025. No date has been published as of 4 August 2026.
- Expected late January 2027 — fiscal 2026 full-year results and fiscal 2027 outlook, together with the annual dividend increase. Fiscal 2025 results were released on 29 January 2026. Not yet announced.
- Expected May 2027 — 2027 Annual Meeting of Shareholders. The 2026 meeting was held virtually on 6 May 2026. Not yet announced.
- 31 Jul 2026 — most recent quarterly dividend of $0.88 per share paid, to holders of record on 30 June 2026, as declared on 7 May 2026.
Stryker does not hold a regular investor day, and no analyst day has been scheduled for 2026 or 2027. The company's product pipeline runs through FDA 510(k) clearances, which carry no published decision calendar, so there are no fixed regulatory decision dates to track. You can follow the wider macro schedule that drives hospital budgets and healthcare demand on the ChartsView Economic Calendar, and discuss this name with other members in the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 3 August 2026
Abbott Laboratories is one of the few genuinely diversified healthcare companies left. Where most of its peers have narrowed down to a single specialism, Abbott still runs four separate businesses under one roof — medical devices, diagnostics, nutrition and branded generic medicines — and in March 2026 it added a fifth growth engine by buying Exact Sciences for roughly $21bn. This report walks through what Abbott actually sells, what the numbers say, and what has to go right or wrong from here. It uses only company filings, press releases and published market data. There are no analyst ratings or price targets anywhere in it.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Abbott Laboratories |
| Ticker / Exchange | ABT / New York Stock Exchange |
| Sector | Healthcare — medical devices, diagnostics, nutrition, established pharmaceuticals |
| Founded | 1888, Chicago, Illinois |
| Headquarters | Abbott Park, Illinois, United States |
| CEO / Leadership | Robert B. Ford — Chairman and Chief Executive Officer (CEO since March 2020, Chairman since December 2021) |
| Employees | Approximately 115,000 (FY2025 results release) |
| Fiscal year end | 31 December |
| Share price | $105.70 (close, 31 July 2026) |
| Market cap | Approximately $184.1bn (1,741.8m shares outstanding × $105.70) |
| Revenue (FY2025) | $44,328m |
| Net income (FY2025, GAAP) | $6,524m |
| Adjusted diluted EPS (FY2025) | $5.15 |
| Dividend | $0.63 per share per quarter ($2.52 annualised); 54 consecutive years of increases |
| R&D spend (FY2025) | $2,942m, or 6.6% of sales |
2. Bull and Bear Case
Bull Case
- Four independent revenue engines: Medical Devices, Diagnostics, Nutrition and Established Pharmaceuticals each generated between $5.5bn and $21.4bn in FY2025, which means no single product cycle or reimbursement decision determines the whole company's year.
- Libre is a consumable, not a one-off sale: continuous glucose monitoring sales reached $2.0bn in the fourth quarter of 2025 alone, up 15% reported, and the business model depends on patients replacing sensors every 10 to 14 days rather than on winning a new capital sale each time.
- Electrophysiology has a new engine: the Volt pulsed field ablation system was approved by the FDA on 22 December 2025, giving Abbott a US entry into the fastest-growing category in cardiac ablation, and electrophysiology grew at a low-teens rate in the second quarter of 2026.
- Exact Sciences adds a whole oncology-diagnostics vertical: the deal closed on 23 March 2026 and brings Cologuard, Oncotype Dx and the Cancerguard multi-cancer screening programme into a diagnostics business that badly needed a growth offset to China pricing.
- Cash generation supports the dividend record: FY2025 operating cash flow was $9,566m against capital expenditure of $2,171m, leaving roughly $7.4bn of free cash flow to fund a payout that has now risen for 54 consecutive years.
Bear Case
- The infant-formula litigation has not gone away: a Missouri verdict of $495m has been upheld on appeal, an Illinois jury returned a further $53m compensatory and $17m punitive award in April 2026, and more than 800 federal necrotising enterocolitis cases remain outstanding.
- China diagnostics looks structurally reset, not cyclical: volume-based procurement cost the Diagnostics segment roughly $700m of FY2025 sales, and management's own framing has been that the China business stabilises rather than returns to growth.
- The Exact Sciences deal was funded with debt and dilutes near-term earnings: Abbott raised roughly $20bn of senior notes in March 2026 and cut its own FY2026 adjusted EPS guidance by about $0.20 to absorb the acquisition before later raising it back.
- Reported earnings look far worse than adjusted earnings: FY2025 GAAP diluted EPS of $3.72 sat 28% below the adjusted figure of $5.15, largely because of $1,682m of intangible amortisation, and the Exact Sciences purchase accounting widens that gap further from 2026.
- CGM is no longer an uncontested market: Dexcom grew FY2025 revenue 16% to $4.66bn and continues to compete directly in Abbott's fastest-growing device category, where reimbursement and pricing pressure tend to arrive together.
3. Business Segments
Abbott reports four segments. The figures below are FY2025 sales as disclosed in the fourth-quarter and full-year 2025 results release.
| Segment | % of revenue | What it is |
|---|---|---|
| Medical Devices — $21,387m | 48.2% | Diabetes Care (FreeStyle Libre CGM, $7,998m), Vascular ($2,995m), Electrophysiology ($2,764m), Rhythm Management ($2,649m), Structural Heart ($2,523m), Heart Failure ($1,448m) and Neuromodulation ($1,010m) |
| Diagnostics — $8,937m | 20.2% | Core laboratory analysers and reagents, molecular, point of care and rapid diagnostics; now also the Exact Sciences oncology-screening portfolio from March 2026 |
| Nutrition — $8,451m | 19.1% | Paediatric nutrition (Similac) and adult nutrition (Ensure, Glucerna) |
| Established Pharmaceuticals — $5,536m | 12.5% | Branded generic medicines sold exclusively in international and emerging markets; no US sales |
| Other / unallocated — $17m | 0.0% | Residual items not allocated to a reportable segment |
4. Business Model and Moat
How it makes money. Abbott sells physical product, not services or licences, and the majority of it is consumed and repurchased. A FreeStyle Libre sensor lasts 10 to 14 days. A core-laboratory analyser placed in a hospital pulls Abbott reagents behind it for the life of the instrument. An implanted device carries leads, programmers and eventual replacement. That structure is why revenue held up at $40.1bn even in 2023, the year COVID testing revenue collapsed.
Where the barrier to entry sits. The moat is regulatory and procedural rather than technological. A Class III device such as Volt or Navitor requires an FDA premarket approval supported by a full clinical trial, which takes years and tens of millions of dollars before a single unit is sold. Once approved, the second barrier is human: electrophysiologists and interventional cardiologists train on a specific platform and are slow to switch. Abbott obtained CE Mark for Volt in March 2025 and FDA approval in December 2025 — a nine-month gap that illustrates how the same product has to clear each jurisdiction separately.
Why the diversification matters commercially. Because four segments sell into overlapping customers — hospitals, labs, pharmacies, retailers — Abbott can fund a launch in one area from the cash flow of another. Established Pharmaceuticals, a low-glamour branded-generics business in emerging markets, throws off cash that helps pay for structural-heart trials. An AA-/Aa3 credit standing then lets the company raise $20bn of notes at short notice, which is what made the Exact Sciences purchase possible.
Scale and reach. Roughly 115,000 employees selling in more than 160 countries gives Abbott the distribution footprint to take a product global quickly once it is approved, and more than 60% of revenue is generated outside the United States.
5. Financial Health
All figures below are taken from Abbott's quarterly and annual results releases and from its filed financial statements. Long-term debt is the non-current balance-sheet figure at each fiscal year end.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| 2021 | 43,075 | +24.5% | $3.94 | $5.21 | $1.82 | $17,296m |
| 2022 | 43,653 | +1.3% | $3.91 | $5.34 | $1.92 | $14,522m |
| 2023 | 40,109 | −8.1% | $3.26 | $4.44 | $2.08 | $13,599m |
| 2024 | 41,950 | +4.6% | $7.64 † | $4.67 | $2.24 | $12,625m |
| 2025 | 44,328 | +5.7% | $3.72 | $5.15 | $2.40 | $9,896m |
† FY2024 GAAP diluted EPS of $7.64 includes a non-cash tax valuation-allowance benefit of roughly $7.5bn. It is not comparable with the other years on a GAAP basis; the adjusted column is the like-for-like series.
The shape of the five years is worth reading carefully. The 2021 spike and the 2023 decline are both COVID testing artefacts — rapid diagnostics inflated 2021 and 2022, then fell away. Stripping that out, the underlying business has compounded in the mid single digits and long-term debt has been reduced every single year, from $17.3bn at the end of 2021 to $9.9bn at the end of 2025. That deleveraging is precisely what created the balance-sheet room to fund Exact Sciences in March 2026.
| Quarter / Half | Revenue ($m) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q2 2026 | 12,600 | $1.31 | $0.53 |
| Q1 2026 | 11,160 | $1.15 | $0.61 |
| Q4 2025 | 11,459 | $1.50 | $1.01 |
| Q3 2025 | 11,369 | $1.30 | $0.94 |
| Q2 2025 | 11,142 | $1.26 | $1.01 |
| Q1 2025 | 10,358 | $1.09 | $0.76 |
| FY2025 total | 44,328 | $5.15 | $3.72 |
Second-quarter 2026 sales of $12.6bn were up 13.0% on a reported basis but only 4.8% on a comparable basis — the gap is Exact Sciences, whose first full quarter of oncology-diagnostics revenue is inside the reported number. The GAAP line tells the other half of the story: GAAP EPS fell to $0.53 while adjusted EPS rose to $1.31, because acquisition accounting and intangible amortisation from the deal now sit in reported earnings.
6. Valuation Metrics
Raw metrics, August 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$184.1bn (1,741.8m shares outstanding × $105.70 close, 31 July 2026) |
| Enterprise value | ~$188.1bn (market cap $184.1bn + total debt $12,929m − cash and short-term investments $8,939m, per the 31 December 2025 balance sheet: long-term debt $9,896m, current portion $3,033m, cash $8,522m, short-term investments $417m) |
| Trailing P/E (GAAP) | ~34.2x ($105.70 / TTM GAAP diluted EPS $3.09, being Q3 2025 $0.94 + Q4 2025 $1.01 + Q1 2026 $0.61 + Q2 2026 $0.53). Distorted upward by Exact Sciences purchase accounting and intangible amortisation; on FY2025 GAAP EPS of $3.72 the multiple is ~28.4x |
| P/E (forward) | ~19.1x ($105.70 / $5.525, the midpoint of Abbott's raised FY2026 adjusted diluted EPS guidance of $5.45–$5.60) |
| P/S (TTM) | ~3.95x ($184.1bn / TTM revenue $46,588m, being the four quarters Q3 2025 through Q2 2026) |
| EV/EBITDA (TTM) | ~16.8x (EV $188.1bn / FY2025 EBITDA $11,169m; EBITDA = operating income $8,053m + depreciation $1,434m + intangible amortisation $1,682m) |
| P/FCF | ~24.9x (market cap $184.1bn / free cash flow $7,395m; FCF = operating cash flow $9,566m − capital expenditure $2,171m per the FY2025 cash flow statement) |
| 52-week high | $137.49 |
| 52-week low | $81.97 (11 May 2026) |
| Short interest (% of float) | 1.07% (18.49m shares short against a float of approximately 1,731.1m shares, latest reported settlement period) |
| Days to cover | ~2.25 days (based on average daily volume of approximately 8.23m shares) |
| Dividend yield | ~2.4% ($2.52 annualised / $105.70) |
Two things stand out. The gap between the trailing GAAP multiple and the forward adjusted multiple is unusually wide right now, and almost all of it is acquisition accounting rather than operating deterioration. And the enterprise value sits only about $4bn above the market cap, because Abbott spent four years paying debt down before it spent $21bn on Exact Sciences — the balance-sheet effect of the March 2026 notes issuance will show up in the FY2026 year-end figures rather than in the FY2025 ones used above.
If you want to look at the price action alongside these numbers, the ChartsView Live Charts page carries the full interactive chart, and the Economic Calendar lists the macro releases that tend to move large-cap healthcare.
7. What Are They Building
Abbott spent $2,942m on research and development in FY2025, equal to 6.6% of sales. That budget is spread across all four segments rather than concentrated in one, which is why the pipeline reads as a list of separate races rather than a single bet.
- Dual glucose-ketone sensing. Abbott secured CE Mark on 27 May 2026 for the Libre Duo, described by the company as the world's first dual glucose-ketone sensor. European launches are planned for later in 2026. The US filing is outstanding, with approval expected in the second half of 2026.
- Consumer biowearables. Lingo and Libre Rio extend the Libre sensor platform beyond prescribed diabetes management into over-the-counter consumer metabolic tracking, opening a market that does not depend on reimbursement.
- Pulsed field ablation. Volt received FDA approval on 22 December 2025 on the strength of the VOLT-AF IDE trial, which reported 93.1% freedom from arrhythmia at six months in paroxysmal atrial fibrillation and 81.9% in persistent cases. Abbott followed with CE Mark for TactiFlex Duo, a catheter that can deliver both radiofrequency and pulsed field energy.
- Structural heart. TriClip for tricuspid repair and the Navitor transcatheter aortic valve both grew at double-digit rates in FY2025, and the Tendyne transcatheter mitral valve system was approved by the FDA in May 2025.
- Peripheral vascular. Esprit BTK, a resorbable scaffold for below-the-knee peripheral artery disease, carries CE Mark and addresses a condition that has historically had few durable device options.
- Oncology diagnostics. The integration of Exact Sciences brings Cologuard colorectal screening, Oncotype Dx recurrence testing, Oncodetect molecular residual disease testing and the Cancerguard multi-cancer early detection programme into Abbott's diagnostics business.
8. Competitive Landscape
Abbott does not have a single competitor that overlaps with all four of its segments. It meets Medtronic and Boston Scientific in cardiac rhythm and electrophysiology, Dexcom in glucose monitoring, Danaher and Becton Dickinson in diagnostics, and Johnson & Johnson across MedTech generally.
| Peer | Market cap (August 2026) | Key 2025 metric |
|---|---|---|
| Johnson & Johnson (JNJ) | ~$618bn (31 July 2026) | FY2025 total revenue of $94.2bn, up 6.0%, of which MedTech contributed $33.8bn |
| Danaher (DHR) | ~$137bn (31 July 2026) | FY2025 revenue of $24.6bn, up 3.0%, with adjusted diluted EPS of $7.80 |
| Stryker (SYK) | ~$127bn (13 July 2026) | FY2025 revenue of approximately $25.1bn |
| Medtronic (MDT) | ~$109bn (31 July 2026) | FY2026 revenue of $36.4bn to April 2026, up 8.4% reported, the strongest growth in ten years |
| Boston Scientific (BSX) | ~$71bn (June 2026) | FY2025 net sales of approximately $20.1bn, up 19.9% reported, with adjusted EPS of $3.06 |
| Becton Dickinson (BDX) | ~$45bn (June 2026) | FY2025 revenue of $21.84bn for the year to September 2025, up 8.2% |
| Dexcom (DXCM) | ~$29.6bn (17 July 2026) | FY2025 revenue of $4.662bn, up 16%, entirely in continuous glucose monitoring |
Peer market capitalisations are drawn from different dates in June and July 2026 and should be treated as approximate rather than simultaneous snapshots.
9. Insider Activity
Chairman and Chief Executive Officer Robert B. Ford is the name to watch in Abbott's 2026 filings. He made an open-market purchase in January 2026 while the shares were falling toward what would become their 52-week low, which is a different signal from the routine tax-withholding dispositions that make up most executive Form 4 activity at a company of this size. Director John G. Stratton bought in May 2026, closer still to the low.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Robert B. Ford (Chairman & CEO) | 23 Jan 2026 | Open-market purchase | 18,800 | $107.13 | ~$2,013,966 | Discretionary purchase |
| Robert B. Ford (Chairman & CEO) | 27 Feb 2026 | Disposition | 30,308 | $116.26 | ~$3,523,607 | Tax withholding on vesting |
| Mary K. Moreland (EVP) | 27 Feb 2026 | Disposition | 4,630 | $116.26 | ~$538,284 | Tax withholding on vesting |
| Mary K. Moreland (EVP) | 2 Mar 2026 | Open-market sale | 613 | $115.58 | ~$70,851 | Not specified in filing summary |
| John G. Stratton (Director) | 7 May 2026 | Open-market purchase | 2,000 | $86.82 | ~$173,640 | Discretionary purchase |
Values are calculated from the reported share counts and prices and are approximate. Readers should verify individual transactions directly against the Form 4 filings on SEC EDGAR before drawing conclusions.
10. Key Risks
- Preterm infant-formula litigation: a $495m Missouri verdict against Abbott has been upheld on appeal, an Illinois jury awarded a further $53m in compensatory and $17m in punitive damages in April 2026, and more than 800 federal necrotising enterocolitis cases remain active against Abbott and Mead Johnson. The tail risk here is not one verdict but the aggregate of many.
- China volume-based procurement: centralised tender pricing removed roughly $700m of Diagnostics sales in FY2025, and because Abbott held 40% to 45% share in some assay categories it absorbed the full price cut without a volume offset. Management's expectation has been stabilisation rather than recovery.
- Acquisition integration and leverage: Exact Sciences was bought for roughly $21bn and funded with about $20bn of new senior notes. It reduced FY2026 adjusted EPS guidance by around $0.20 on announcement. Integration slippage or slower-than-expected Cologuard and Cancerguard uptake would leave Abbott carrying the interest cost without the growth.
- Competitive pressure in continuous glucose monitoring: Libre is Abbott's single largest growth driver at $7,998m of FY2025 sales, and Dexcom grew 16% in the same year. Sustained competition in a reimbursed category usually shows up as price erosion before it shows up as share loss.
- Nutrition volumes and pricing: Nutrition sales fell 8.9% on a reported basis in the fourth quarter of 2025 on lower volumes and deliberate price actions. The recovery depends on 2026 product launches landing as planned.
- Currency and trade policy: more than 60% of Abbott's revenue is earned outside the United States, so dollar strength is a recurring drag on reported growth. Abbott has separately flagged tariff uncertainty and is investing to diversify its manufacturing footprint in response.
- Regulatory compliance cost: European Medical Device Regulation and In Vitro Diagnostic Regulation compliance appears as a recurring specified item in every quarterly non-GAAP reconciliation, and the underlying cost does not go away simply because it is excluded from adjusted earnings.
11. Recent Developments
- 12 Dec 2025 — Dividend raised for a 54th consecutive year. The board declared its 408th consecutive quarterly dividend and increased the rate to $0.63 per share, payable 13 February 2026.
- 22 Dec 2025 — FDA approves the Volt pulsed field ablation system. Approval gave Abbott its first US pulsed field ablation offering for atrial fibrillation, supported by VOLT-AF IDE trial results of 93.1% arrhythmia-free survival at six months in paroxysmal patients.
- 22 Jan 2026 — Fourth-quarter and full-year 2025 results. FY2025 sales of $44,328m, up 5.7%, GAAP diluted EPS of $3.72 and adjusted diluted EPS of $5.15, up 10%. Abbott issued initial FY2026 guidance of 6.5% to 7.5% comparable sales growth and $5.55 to $5.80 adjusted EPS.
- 23 Mar 2026 — Exact Sciences acquisition completed. Abbott closed the roughly $21bn purchase, funded through a $20bn senior notes offering completed earlier in March, adding Cologuard, Oncotype Dx, Oncodetect and Cancerguard to its diagnostics portfolio.
- 10 Apr 2026 — Illinois jury returns a further formula verdict. Four mothers were awarded $53m in compensatory and $17m in punitive damages in a state-court trial concerning Similac Special Care 24. Abbott has said it will appeal.
- 16 Apr 2026 — First-quarter 2026 results and guidance reset. Sales of $11,160m, GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15. Abbott lowered its FY2026 adjusted EPS range to $5.38 to $5.58 to absorb roughly $0.20 of Exact Sciences dilution.
- 27 May 2026 — CE Mark for dual glucose-ketone sensing. Abbott secured European approval for what it describes as the world's first dual glucose-ketone sensor, with launches planned in selected European markets later in 2026.
- 12 Jun 2026 — 410th consecutive quarterly dividend declared. The board declared $0.63 per share, payable 17 August 2026 to shareholders of record on 15 July 2026.
- 16 Jul 2026 — Second-quarter 2026 results and raised guidance. Sales of $12.6bn, up 13.0% reported and 4.8% comparable, with adjusted diluted EPS of $1.31 and GAAP diluted EPS of $0.53. Abbott raised its FY2026 adjusted EPS range to $5.45 to $5.60 and reaffirmed comparable sales growth guidance of 6.5% to 7.5%. Growth was led by low-teens electrophysiology and high-single-digit rhythm management, diabetes care and heart failure, plus the first full quarter of Exact Sciences revenue. Abbott returned $2.1bn to shareholders in the quarter.
12. Key Dates and Catalysts
- 17 Aug 2026 — payment date for the 410th consecutive quarterly dividend of $0.63 per share; record date was 15 July 2026
- Expected Oct 2026 — third-quarter 2026 results. Third-party earnings calendars indicate 21 October 2026, but this has not been confirmed on Abbott's own investor relations calendar at the time of writing
- Expected Dec 2026 — the board's customary December dividend declaration, which has carried an increase in each of the last 54 years
- Expected H2 2026 — FDA decision on the Libre Duo dual glucose-ketone sensor, already CE-marked in Europe since 27 May 2026
- Expected 2026 — further European market launches of Libre Duo following the May 2026 CE Mark
- TBD — appellate rulings and further state-court trial dates in the necrotising enterocolitis infant-formula litigation, where more than 800 federal cases remain outstanding
Abbott's fiscal year ends on 31 December, so the fourth-quarter and full-year 2026 results, together with initial FY2027 guidance, would normally follow in late January 2027. Readers tracking these dates alongside macro releases may find the ChartsView Economic Calendar useful, and discussion of individual names takes place on the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 3 August 2026
Medtronic has just posted its strongest revenue growth in a decade while simultaneously trying to detach an entire business unit from itself. Fiscal 2026 revenue of $36.4bn was up 8.4%, driven by an ablation franchise that nearly doubled, and in March 2026 the company floated its diabetes arm as MiniMed on Nasdaq while retaining roughly 90% of it. This report sets out what Medtronic sells, what the filings actually say, and what has to happen for the separation and the growth story to hold together. Every figure comes from company filings and published market data. There are no analyst ratings or price targets in it.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Medtronic plc |
| Ticker / Exchange | MDT / New York Stock Exchange |
| Sector | Healthcare — medical devices and healthcare technology |
| Founded | 1949 |
| Headquarters | Registered office Galway, Ireland; operational headquarters Minneapolis, Minnesota, United States |
| CEO / Leadership | Geoffrey S. Martha — Chairman and Chief Executive Officer |
| Employees | More than 95,000 full-time employees, 43% of them in the United States or Puerto Rico |
| Fiscal year end | Late April; FY2026 ended 24 April 2026 |
| Share price | $85.39 (close, 31 July 2026) |
| Shares outstanding | 1,280,045,190 ordinary shares (as of 12 June 2026) |
| Market cap | Approximately $109.3bn (1,280.0m shares × $85.39) |
| Revenue (FY2026) | $36,364m, up 8.4% reported and 5.8% organic |
| Net income (FY2026, GAAP) | $4,801m attributable to Medtronic, up 3.0% |
| Non-GAAP diluted EPS (FY2026) | $5.53 |
| Dividend | $0.72 per share per quarter from Q1 FY2027 ($2.88 annualised); 49 consecutive years of increases |
| R&D spend (FY2026) | $2,873m, or 7.9% of net sales |
2. Bull and Bear Case
Bull Case
- Growth has genuinely re-accelerated: FY2026 revenue of $36,364m was up 8.4% reported and 5.8% organic, the fastest annual growth in ten years, and the fourth quarter alone delivered $9,807m with non-GAAP EPS of $1.55.
- Pulsed field ablation is compounding fast: Cardiac Ablation Solutions revenue grew 78% globally and 124% in the United States in the fourth quarter of FY2026, taking eight points of US share, driven by the PulseSelect and Affera Sphere-9 and Sphere-360 catheters.
- Hugo gives Medtronic a real seat in soft-tissue robotics: the system holds FDA clearance for urologic procedures, and on 3 June 2026 Medtronic filed 510(k) submissions to extend it into general surgery and gynaecology, the two largest robotic procedure pools.
- The MiniMed separation simplifies the story: the diabetes arm floated on Nasdaq on 6 March 2026 and full separation is targeted within FY2027, which would leave three focused portfolios and put a market price on an asset previously buried inside a conglomerate.
- Capital return and outside pressure are aligned: the dividend rose to $0.72 per quarter for a 49th consecutive annual increase, while Elliott Investment Management's stake has already produced two new board directors and dedicated growth and operational-efficiency committees.
Bear Case
- Earnings growth is not keeping pace with revenue: FY2026 non-GAAP EPS of $5.53 was barely ahead of FY2022's $5.55, and the company disclosed that constant-currency EPS growth was negative 2.0% in FY2026 with a $0.15 currency benefit flattering the reported figure.
- The balance sheet carries real leverage: long-term debt stood at $26,173m at 24 April 2026 with a further $1,788m current, against $9.2bn of cash and investments, and the company's own risk factors flag refinancing and credit-rating exposure.
- The separation is unfinished and complex: Medtronic still consolidates the diabetes business, still owns roughly 90% of MiniMed, has not finalised the structure of the final step, and is running that programme alongside CathWorks, Scientia Vascular, SPR Therapeutics and a Merit Medical agreement simultaneously.
- Competition is intensifying in every growth area at once: Intuitive Surgical in robotics, Boston Scientific and Johnson & Johnson in pulsed field ablation, and Abbott and Dexcom in glucose monitoring — and the FY2026 risk factors name GLP-1 drugs as an alternative to device-based therapy.
- Policy and pricing headwinds are quantified, not theoretical: tariffs cost 80 basis points of operating margin in the fourth quarter and 50 basis points across FY2026, while China volume-based procurement continues to force price concessions in a market representing roughly 6% of revenue.
3. Business Segments
Medtronic reported three segments in FY2026. Diabetes ceased to be a reportable segment in the fourth quarter following the MiniMed initial public offering, but it remains fully consolidated in group revenue — it is not treated as a discontinued operation. Figures below are FY2026 revenue.
| Segment | % of revenue | What it is |
|---|---|---|
| Cardiovascular Portfolio — $13,976m | 38.4% | Cardiac rhythm and heart failure devices, cardiac ablation including pulsed field, structural heart and aortic products such as Evolut transcatheter valves, and coronary and peripheral vascular including renal denervation. Grew 12.0% in FY2026 |
| Neuroscience Portfolio — $10,287m | 28.3% | Cranial and spinal technologies including navigation and robotics, specialty therapies covering neurovascular stroke devices, ENT and pelvic health, and neuromodulation for pain and movement disorders. Grew 4.5% |
| Medical Surgical Portfolio — $8,815m | 24.2% | Surgical stapling, energy devices, hernia mesh, GI endoscopy and the Hugo robotic-assisted surgery system, plus acute care patient monitoring and airway management. Grew 4.9% |
| Diabetes (no longer a reportable segment, still consolidated) — $3,112m | 8.6% | Insulin pumps, continuous glucose monitoring and consumables, now operated through the separately listed MiniMed. Grew 12.9% |
| Other — $174m | 0.5% | Exited and divested businesses, including the fully divested Dutch obesity clinic |
4. Business Model and Moat
How it makes money. Medtronic sells devices and the consumables that go with them, through a direct sales force organised by physician specialty and supplemented by distributors. A meaningful share of revenue comes from consignment inventory held at the hospital, meaning the product sits on the shelf and Medtronic recognises revenue as it is used. No single customer accounts for more than 10% of net sales, so the revenue base is spread across thousands of hospitals, group purchasing organisations and integrated delivery networks worldwide.
Where the switching costs live. The moat is built on training and installed base rather than patents alone. A cardiologist who implants Medtronic pacemakers works within Medtronic's programmer and remote-monitoring ecosystem; a spine surgeon trained on StealthStation navigation is unlikely to relearn a rival platform mid-career. Implanted devices then generate a decade or more of follow-on revenue in leads, replacements and consumables. That is why an installed base built over seventy-five years is worth more than any individual product approval.
Regulation cuts both ways. FDA premarket approval, European Medical Device Regulation and China NMPA registration are formidable barriers to a new entrant — but they are equally a brake on Medtronic itself. Hugo's US path has been indication by indication: urologic clearance first, then separate 510(k) submissions in June 2026 for general surgery and gynaecology. The same regulation that protects the franchise slows its expansion.
What erodes the moat. Government and group tender pricing is the counterweight. Chinese volume-based procurement, national tenders and payer utilisation management all compress price on products where Medtronic's clinical position is otherwise secure, and the FY2026 risk factors say so explicitly.
5. Financial Health
Medtronic's fiscal year ends in late April, so FY2026 covers the twelve months to 24 April 2026. Figures below are taken from Medtronic's results releases and filed financial statements. Long-term debt is the non-current balance-sheet figure including finance lease obligations at each fiscal year end.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| 2022 (to 29 Apr 2022) | 31,686 | +5.2% | $3.73 | $5.55 | $2.52 | $20,372m |
| 2023 (to 28 Apr 2023) | 31,227 | −1.4% | $2.82 | $5.29 | $2.72 | $24,344m |
| 2024 (to 26 Apr 2024) | 32,364 | +3.6% | $2.76 | $5.20 | $2.76 | $23,932m |
| 2025 (to 25 Apr 2025) | 33,537 | +3.6% | $3.61 | $5.49 | $2.80 | $25,642m |
| 2026 (to 24 Apr 2026) | 36,364 | +8.4% | $3.73 | $5.53 | $2.84 | $26,173m |
The five-year picture is a company that has grown revenue by roughly $4.7bn while producing almost exactly the same adjusted earnings per share it produced in FY2022. Adjusted EPS of $5.53 in FY2026 sits fractionally below the $5.55 of FY2022. Long-term debt rose by nearly $6bn over the same span. Whatever the top line has been doing, the earnings line has been running to stand still — and FY2026's improvement was helped by a $0.15 currency tailwind, with constant-currency EPS growth of negative 2.0%.
| Quarter / Half | Revenue ($m) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q4 FY2026 (to 24 Apr 2026) | 9,807 | $1.55 | $0.96 |
| Q3 FY2026 (to 23 Jan 2026) | 9,000 | $1.36 | $0.89 |
| Q2 FY2026 (to 24 Oct 2025) | 9,000 | $1.36 | $1.07 |
| Q1 FY2026 (to 25 Jul 2025) | 8,600 | $1.26 | $0.81 |
| FY2026 total | 36,364 | $5.53 | $3.73 |
Quarterly revenue figures for Q1 to Q3 FY2026 are as reported to the nearest $0.1bn in the respective press releases. First-quarter FY2027 results, covering the quarter ended in late July 2026, had not been released at the time of writing; Medtronic confirmed on 20 July 2026 that they will be published on 1 September 2026.
6. Valuation Metrics
Raw metrics, August 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$109.3bn (1,280.0m shares outstanding × $85.39 close, 31 July 2026) |
| Enterprise value | ~$128.0bn (market cap $109.3bn + total debt $27,961m − cash and investments $9,220m, per the 24 April 2026 balance sheet: long-term debt $26,173m, current debt $1,788m, cash $1,949m, short-term investments $7,271m) |
| Trailing P/E (GAAP) | ~22.9x ($85.39 / FY2026 GAAP diluted EPS $3.73) |
| P/E (forward) | ~14.4x ($85.39 / $5.95, the midpoint of Medtronic's FY2027 non-GAAP diluted EPS guidance of $5.90–$6.00) |
| P/S (TTM) | ~3.01x ($109.3bn / FY2026 revenue $36,364m) |
| EV/EBITDA (TTM) | ~13.6x (EV $128.0bn / FY2026 EBITDA $9,425m; EBITDA = GAAP operating income $6,467m + depreciation and amortisation $2,958m from the cash flow statement) |
| P/FCF | ~20.1x (market cap $109.3bn / free cash flow $5,426m; FCF = operating cash flow $7,330m − capital expenditure $1,904m per the FY2026 cash flow statement, matching the company's own reported free cash flow) |
| 52-week high | $106.33 (26 November 2025) |
| 52-week low | $73.31 (2 June 2026) |
| Short interest (% of float) | ~1.49% (19.09m shares short, as of the 23 July 2026 settlement date) |
| Days to cover | n/a — no days-to-cover figure was published alongside the 23 July 2026 short-interest reading; verify at MarketBeat or Nasdaq short-interest pages for the current settlement period |
| Dividend yield | ~3.4% ($2.88 annualised / $85.39) |
The most striking number here is the gap between the trailing and forward multiples. Medtronic trades at roughly 22.9 times reported GAAP earnings but around 14.4 times the midpoint of its own FY2027 non-GAAP guidance, and the difference is amortisation, restructuring and separation costs rather than a step change in the operating business. The enterprise value sits nearly $19bn above the market cap, which is a reminder that the debt load is material relative to the equity.
The ChartsView Live Charts page carries the full interactive chart if you want to see how this valuation has moved over the last twelve months.
7. What Are They Building
Medtronic spent $2,873m on research and development in FY2026, equal to 7.9% of net sales, and supplemented it with a run of bolt-on acquisitions announced in the same year.
- Hugo robotic-assisted surgery. Cleared by the FDA for urologic procedures, with first US commercial cases following. On 3 June 2026 Medtronic filed 510(k) submissions to expand Hugo into general surgery and gynaecology and to clear the LigaSure RAS vessel sealer, having completed enrolment in the Embrace Gynecology clinical study.
- Pulsed field ablation. The PulseSelect single-shot catheter, the Affera Sphere-9 focal catheter capable of both radiofrequency and pulsed field energy, and the Affera Sphere-360 all run on the Affera mapping and navigation system. This is the fastest-growing part of the company, up 78% globally in the fourth quarter of FY2026.
- Renal denervation. The Centers for Medicare and Medicaid Services finalised a National Coverage Determination for renal denervation on 28 October 2025, covering the Symplicity Spyral system for uncontrolled hypertension, with the coding transmittal published on 19 March 2026. Transitional pass-through payment status has applied to the catheter since 1 January 2025.
- Structural heart. The Evolut transcatheter aortic valve family, including PRO+, FX and FX+, sits inside a structural heart and aortic business that generated $3,817m in FY2026, up 7.4%.
- Surgical navigation. The Stealth AXiS surgical system received FDA clearance for spine, cranial and ENT indications and CE Mark for spine and cranial, integrating robotic guidance with StealthStation navigation.
- Diabetes technology through MiniMed. EMEA commercial launch of the MiniMed Go smart multiple-daily-injection system with the Simplera sensor began on 25 February 2026, following FDA approval of the US version in January 2026 with launch expected later in 2026.
- Acquisitions bolted on. CathWorks closed on 20 April 2026 for $585m in coronary and peripheral vascular, and in May 2026 Medtronic announced intentions to acquire Scientia Vascular in neurovascular and SPR Therapeutics in neuromodulation, an agreement with Merit Medical for ViaVerte, and an investment in Pulnovo Medical.
8. Competitive Landscape
Medtronic competes with a different company in almost every one of its franchises. Abbott and Boston Scientific meet it in cardiac rhythm and ablation, Intuitive Surgical dominates the robotics market Hugo is entering, Edwards Lifesciences is its main rival in transcatheter valves, and Abbott and Dexcom compete with the diabetes business it is separating.
| Peer | Market cap (August 2026) | Key 2025 metric |
|---|---|---|
| Johnson & Johnson (JNJ) | ~$618bn (31 July 2026) | FY2025 total revenue of $94.2bn, up 6.0%, with MedTech contributing $33.8bn |
| Abbott Laboratories (ABT) | ~$184bn (31 July 2026) | FY2025 sales of $44.3bn, up 5.7% reported, with adjusted diluted EPS of $5.15 |
| Stryker (SYK) | ~$127bn (13 July 2026) | FY2025 revenue of approximately $25.1bn |
| Boston Scientific (BSX) | ~$71bn (June 2026) | FY2025 net sales of approximately $20.1bn, up 19.9% reported, with adjusted EPS of $3.06 |
| Edwards Lifesciences (EW) | ~$48bn (July 2026) | FY2025 revenue of approximately $6.07bn, concentrated in structural heart |
| Becton Dickinson (BDX) | ~$45bn (June 2026) | FY2025 revenue of $21.84bn for the year to September 2025, up 8.2% |
Peer market capitalisations are drawn from different dates in June and July 2026 and should be treated as approximate rather than simultaneous snapshots.
9. Insider Activity
Chairman and Chief Executive Officer Geoffrey S. Martha remains in post and appears in the 2026 filings only through routine tax-related share withholding on vesting rather than open-market activity. Medtronic insiders reported seven transactions in June 2026 totalling approximately $5.28m, of which five were tax-related dispositions and two were open-market sales. There were no open-market purchases by insiders in the period reviewed.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Geoffrey S. Martha (Chairman & CEO) | 4 Jun 2026 | Disposition | 41,936 | $83.32 | ~$3,494,088 | Tax withholding on vesting |
| Matthew R. Walter (SVP, Chief HR Officer) | 4 Jun 2026 | Disposition | 2,840 | $83.32 | ~$236,629 | Tax withholding on performance RSU vesting |
| Harry "Skip" Kiil (Officer) | 8 Jun 2026 | Proposed sale (Form 144) | Not disclosed | Not disclosed | ~$336,000 | Form 144 notice of proposed sale |
| Matthew R. Walter (SVP, Chief HR Officer) | 8 Jul 2026 | Open-market sale | 3,102 | $83.15 | ~$257,931 | Not specified in filing summary |
| Michelle Quinn (EVP, General Counsel) | Jul 2026 | Disposition | 2,069 | $86.88 | ~$179,754 | Tax withholding on RSU vesting |
These entries are drawn from published summaries of SEC Form 4 filings and values are calculated from the reported share counts and prices. Readers should verify individual transactions against the original filings on SEC EDGAR before drawing conclusions.
10. Key Risks
- Separation execution: Medtronic's own risk factors state that expected strategic benefits from the ongoing separation of the diabetes business may not be realised or may take longer than expected. The company still consolidates the unit, still owns roughly 90% of MiniMed, and has not finalised whether the final step is a spin-off, a split-off, a further offering or a combination.
- Simultaneous transaction load: the FY2026 filings explicitly flag the cumulative effect of executing multiple transactions at once. CathWorks, Scientia Vascular, SPR Therapeutics, the Merit Medical agreement and the Pulnovo investment are all layered on top of the MiniMed programme, increasing operational complexity and timing risk.
- Debt and refinancing: total debt of roughly $28.0bn against $9.2bn of cash and investments means a meaningful share of operating cash flow services interest, and the company warns there can be no assurance it will maintain its credit rating if capital-market access tightens.
- Competitive and technological displacement: the risk factors name GLP-1 drugs as an alternative to device-based therapy alongside conventional competition — Intuitive Surgical in robotics, Boston Scientific and Johnson & Johnson in pulsed field ablation, and Abbott and Dexcom in glucose monitoring.
- China pricing and intellectual property: national and provincial volume-based procurement programmes in China require significant price concessions in a market representing roughly 6% of total revenue, and China is separately flagged as a weak point for intellectual-property protection.
- Product liability and recalls: quality problems have previously led to recalls and safety alerts, and implanted devices carry long-tail liability. Medtronic is also engaged in US Tax Court litigation with the IRS over Puerto Rico transfer pricing, remanded back to the Tax Court in September 2025, which the company says could materially affect its financial condition.
- Tariffs and currency: tariffs reduced operating margin by 80 basis points in the fourth quarter of FY2026 and 50 basis points across the full year, while currency added $819m to FY2026 revenue and $0.15 to EPS — a tailwind that reverses if the dollar strengthens.
- Hospital capital spending and reimbursement: demand depends on hospital purchasing decisions, group purchasing tender dynamics and payer coverage policy, any of which can change physician adoption and procedure volumes without warning.
11. Recent Developments
- 28 Oct 2025 — CMS finalises renal denervation coverage. A National Coverage Determination for renal denervation covering the Symplicity Spyral system gave Medicare patients with uncontrolled hypertension access to the procedure, removing the principal reimbursement obstacle to the therapy.
- 18 Nov 2025 — Second-quarter FY2026 results. Revenue of $9.0bn, up 6.6% reported and 5.5% organic and 75 basis points ahead of guidance, with GAAP EPS of $1.07 and non-GAAP EPS of $1.36. Cardiac Ablation Solutions revenue rose 71% globally and 128% in the United States, and full-year guidance was raised.
- 17 Feb 2026 — Third-quarter FY2026 results. Revenue of $9.0bn, up 8.7% reported and 6.0% organic, the strongest enterprise growth in ten quarters, with GAAP EPS of $0.89 and non-GAAP EPS of $1.36. Cardiac Ablation Solutions grew 80% globally and 137% in the United States.
- 25 Feb 2026 — MiniMed Go launches across EMEA. Commercial rollout of the MiniMed Go smart multiple-daily-injection system with the Simplera sensor began in Europe, the Middle East and Africa, following FDA approval of the US version in January 2026.
- 5 Mar 2026 — MiniMed prices its initial public offering. The diabetes business priced 28,000,000 shares at $20.00, below the marketed range. Trading began on the Nasdaq Global Select Market under the ticker MMED on 6 March 2026 and the offering closed on 9 March 2026 with roughly $538m of net proceeds. Medtronic retained approximately 90% of the shares.
- 20 Apr 2026 — CathWorks acquisition completed. Medtronic closed its $585m purchase of CathWorks, expanding the coronary and peripheral vascular portfolio, having announced its intent to exercise the option on 3 February 2026.
- 3 Jun 2026 — Fourth-quarter and full-year FY2026 results. Revenue of $36,364m, up 8.4% reported and 5.8% organic and the highest annual growth in ten years, with GAAP diluted EPS of $3.73 and non-GAAP diluted EPS of $5.53. The quarterly dividend was raised to $0.72 for a 49th consecutive annual increase, and FY2027 guidance was issued at 6.75% to 7.25% organic growth and $5.90 to $6.00 non-GAAP EPS.
- 3 Jun 2026 — Hugo filings and further acquisitions announced. Alongside results, Medtronic filed 510(k) submissions to expand Hugo into general surgery and gynaecology, disclosed FDA clearance of the Stealth AXiS system for spine, cranial and ENT, and announced intentions to acquire Scientia Vascular and SPR Therapeutics.
- 20 Jul 2026 — First-quarter FY2027 reporting date confirmed. Medtronic announced that results for the quarter ended in late July 2026 will be released on 1 September 2026, with a news release at 5:45am Central Time and a webcast at 6:45am.
12. Key Dates and Catalysts
- 1 Sep 2026 — first-quarter FY2027 results, news release at 5:45am Central Time with webcast at 6:45am; the first quarter to be reported under the new three-segment structure
- 17 Jul 2026 — payment date of the raised $0.72 quarterly dividend declared on 3 June 2026, with a record date of 26 June 2026
- Expected Sep 2026 — declaration of the second-quarter FY2027 dividend, following Medtronic's usual quarterly cadence
- Expected Dec 2026 — completion of the full MiniMed separation, which Medtronic has targeted within FY2027 and by the end of calendar 2026; the final structure had not been fixed as of the June 2026 results
- Expected 2027 — FDA decisions on the Hugo general surgery and gynaecology 510(k) submissions filed on 3 June 2026
- TBD — resolution of the US Tax Court transfer-pricing litigation with the IRS, remanded back to the Tax Court in September 2025
Medtronic's fiscal calendar means its full-year results and forward guidance land in late May or early June each year rather than in January, which is worth remembering when comparing it against calendar-year peers such as Abbott. Upcoming macro releases that affect the sector are listed on the ChartsView Economic Calendar, and readers can discuss individual holdings on the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 17 July 2026
Thermo Fisher Scientific is the world's largest life-sciences tools and services company, supplying instruments, reagents, consumables, software and outsourced services to pharmaceutical, biotech, academic, government, clinical and industrial customers. The company reported full-year 2025 revenue of $44.56bn and adjusted EPS of $22.87, and lifted its 2026 outlook after a first quarter that beat expectations. With roughly $45bn of remaining performance obligations in its biopharma-services backlog, a serial acquisition model that most recently added clinical-trial data specialist Clario, and a large recurring consumables base, Thermo Fisher sits at the centre of the global research and drug-development economy. This report walks through the company's structure, financial health, valuation and the debate between bulls and bears. For live pricing see our Live Charts and upcoming catalysts on the Economic Calendar.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Thermo Fisher Scientific Inc. |
| Ticker / Exchange | TMO (NYSE) |
| Sector | Healthcare — Life Sciences Tools & Services |
| CEO / Leadership | Marc N. Casper (Chairman, President & Chief Executive Officer) |
| Employees | ~125,000 (as of 31 Dec 2025) |
| Headquarters | Waltham, Massachusetts, USA |
| Market cap | ~$196bn (14 Jul 2026) |
| Share price | ~$535 (mid-Jul 2026) |
| Revenue (FY2025) | $44.56bn |
| GAAP diluted EPS (FY2025) | $17.74 |
| Adjusted EPS (FY2025) | $22.87 |
| Dividend / share (FY2025 declared) | $1.72 |
| Next earnings | 23 Jul 2026 (Q2 2026) |
2. Bull vs Bear
Bull Case
- Unrivalled scale and breadth: At $44.6bn of revenue across four segments, Thermo Fisher is the largest company in life-sciences tools, giving it distribution reach, cross-selling and purchasing power that smaller rivals cannot match.
- Recurring, consumables-led revenue: A large share of sales comes from reagents, consumables and services that customers reorder continuously, producing a razor/razor-blade model with pricing power and visibility, backed by roughly $45bn of biopharma-services performance obligations.
- Proven M&A compounding: Management has a long record of accretive acquisitions; the $8.9bn Clario deal (closed March 2026) adds clinical-trial endpoint data, and the company still lifted 2026 guidance after folding it in.
- Strong cash generation and returns: Free cash flow of roughly $6.3bn in 2025 funded about $3.6bn of dividends and buybacks alongside continued M&A, supporting a self-reinforcing capital-allocation engine.
- Secular demand tailwinds: Long-run growth in biologics, cell and gene therapy, diagnostics and bioproduction underpins the addressable market as the post-COVID normalisation runs its course.
Bear Case
- Soft organic growth: Organic revenue rose only about 1% in Q1 2026; headline growth is leaning heavily on acquisitions and currency rather than underlying volume.
- Funding and policy pressure: Exposure to academic and government research budgets (including NIH funding scrutiny) and to China leaves a meaningful slice of demand vulnerable to policy shifts.
- Rising debt load: Total borrowings climbed toward roughly $43bn after the Clario financing, increasing interest cost and reducing balance-sheet flexibility.
- Wide GAAP-to-adjusted gap: GAAP EPS of $17.74 sits well below adjusted EPS of $22.87, largely because of about $1.7bn of annual intangible amortisation tied to past deals.
- Cyclical end-market risk: Pharma and biotech capital-equipment spending is cyclical, and tariff or trade-policy disruption could pressure both cost and demand.
3. Business Segments
Thermo Fisher reports in four segments. Segment revenues below are gross of intersegment eliminations of roughly $2.0bn, which reconcile to consolidated revenue of $44.56bn.
| Segment | % of revenue | What it is |
|---|---|---|
| Laboratory Products & Biopharma Services | ~52% ($23.98bn) | Lab equipment, consumables, channel/distribution, plus pharma services (CDMO, clinical trial logistics, the former PPD clinical-research business) |
| Life Sciences Solutions | ~22% ($10.37bn) | Reagents, instruments and consumables for biological research, genetic analysis and bioproduction |
| Analytical Instruments | ~16% ($7.55bn) | Mass spectrometry, chromatography, electron microscopy and chemical-analysis instruments and software |
| Specialty Diagnostics | ~10% ($4.68bn) | Clinical diagnostics reagents, immunodiagnostics, microbiology, transplant and allergy testing |
4. Business Model & Moat
How it makes money. The company sells a mix of one-off capital equipment (instruments) and high-margin recurring items (reagents, consumables, service contracts and outsourced pharma services). The recurring base is the profit engine: once an instrument or workflow is embedded in a lab, the customer keeps buying matched consumables and services for years, producing sticky, repeatable revenue.
Why the moat is durable. Switching costs are high because instruments, software, validated methods and regulatory sign-offs are difficult to change once a lab is running. Scale gives Thermo Fisher the widest catalogue and distribution network in the industry, and its balance sheet lets it acquire and integrate targets faster than peers. Brand trust in regulated clinical and pharmaceutical settings reinforces the position.
Where it is vulnerable. The moat is weaker in commoditised lab supplies and in instrument categories where Danaher, Agilent, Waters and Bruker compete hard on performance. Demand tied to research grants and pharma capital budgets can soften quickly in a downturn.
5. Financial Health
All figures below are drawn from Thermo Fisher's SEC filings (10-K, 10-Q) and quarterly earnings press releases. Revenue is on the company's reported basis.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt ($m, YE) |
|---|---|---|---|---|---|---|
| FY2021 | 39,211 | +21.7% | $19.46 | $25.13 | $1.04 | 34,670 |
| FY2022 | 44,915 | +14.5% | $17.63 | $23.24 | $1.20 | 34,278 |
| FY2023 | 42,857 | −4.6% | $15.45 | $21.55 | $1.40 | 34,727 |
| FY2024 | 42,879 | +0.1% | $16.53 | $21.86 | $1.56 | 31,072 |
| FY2025 | 44,556 | +3.9% | $17.74 | $22.87 | $1.72 | 39,172 |
Quarterly detail (most recent first). GAAP EPS for Q4 2025 is derived by subtracting the first three reported quarters from the full-year figure.
| Quarter | Revenue ($m) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 2026 | 11,005 | $5.44 | $4.43 |
| Q4 2025 | 12,215 | $6.57 | $5.21 |
| Q3 2025 | 11,122 | $5.79 | $4.27 |
| Q2 2025 | 10,855 | $5.36 | $4.28 |
| FY2025 total | 44,556 | $22.87 | $17.74 |
The balance sheet carried about $39.2bn of non-current long-term debt plus $3.5bn of current debt at year-end 2025, against roughly $9.9bn of cash and $0.3bn of short-term investments. Operating cash flow was $7.82bn and capital expenditure $1.53bn, giving free cash flow of about $6.3bn.
6. Valuation
Raw metrics, July 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$196bn (14 Jul 2026) |
| Enterprise value | ~$229bn (market cap ~$196bn + total debt ~$42.7bn − cash & ST investments ~$10.1bn per FY2025 balance sheet) |
| Trailing P/E (GAAP) | ~29x (price ~$535 / TTM GAAP EPS ~$18.19, i.e. FY2025 $17.74 − Q1 2025 $3.98 + Q1 2026 $4.43) |
| P/E (forward) | ~21.5x (price ~$535 / FY2026 adjusted EPS guidance midpoint ~$24.88) |
| P/S (TTM) | ~4.3x (market cap ~$196bn / TTM revenue ~$45.2bn) |
| EV/EBITDA (TTM) | ~22x (EV ~$229bn / FY2025 EBITDA ~$10.5bn; EBITDA = operating income $7.75bn + D&A $2.78bn per cash flow statement) |
| P/FCF | ~31x (market cap ~$196bn / FCF ~$6.3bn; FCF = operating cash flow $7.82bn − capex $1.53bn per FY2025 cash flow statement) |
| 52-week high | $643.99 |
| 52-week low | $385.46 |
| Short interest (% of float) | ~1.0% (Benzinga, latest 2026 reading; ~3.9m shares) |
| Days to cover | ~2.8 days |
7. What Are They Building
Thermo Fisher's growth roadmap runs along three lines: acquisitions, capacity and innovation. The largest recent move is the $8.875bn purchase of Clario, closed in March 2026, which bolts clinical-trial endpoint data and decentralised-trial technology onto the existing pharma-services franchise and deepens the company's role across the drug-development lifecycle. Alongside deals, the company continues to invest in bioproduction and pharma-services capacity to serve biologics and cell-and-gene-therapy manufacturing.
On the innovation side, Thermo Fisher used ASMS 2026 and BIO International 2026 to showcase next-generation mass spectrometry, AI-enabled research tools and manufacturing and clinical-development capabilities. It has also expanded forensic and mRNA partnerships, including regulatory clearance of its RapidINTEL Plus DNA cartridge for the FBI's national DNA index and a collaboration with Arcturus Therapeutics to support Phase 3 development of an mRNA cystic-fibrosis therapy. The through-line is embedding Thermo Fisher deeper into regulated, recurring-revenue workflows.
8. Peer Comparison
| Peer | Market cap (Jul 2026) | Key 2025 metric |
|---|---|---|
| Thermo Fisher (TMO) | ~$196bn | FY2025 revenue $44.56bn |
| Danaher (DHR) | ~$141bn | FY2025 revenue $24.6bn |
| Agilent Technologies (A) | ~$37bn | FY2025 (Oct) revenue $6.95bn |
| Waters (WAT) | ~$37bn | FY2025 revenue $3.17bn |
| Revvity (RVTY) | ~$12bn | FY2025 revenue $2.86bn |
9. Insider Activity
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Marc N. Casper (Chairman & CEO) | 05 Mar 2026 | Sale | ~4,000 | $503.66–$519.74 | ~$2.06m | Rule 10b5-1 |
| Marc N. Casper (Chairman & CEO) | 03–04 Mar 2026 | Option exercise & sale | 10,000 | exercise $309.63 | — | Rule 10b5-1 |
| Marc N. Casper (Chairman & CEO) | 28 Aug 2025 | Sale | ~1,411 | $489.74 | ~$0.69m | Open market |
Recent insider activity has been routine sales and option exercises by the CEO under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025, rather than open-market conviction buying or selling. No material insider purchases were reported in the period.
10. Key Risks
- Research-funding and policy risk (Regulatory/Macro): Cuts or delays to academic and government research budgets, including NIH funding pressure, could reduce demand across multiple segments.
- China and geopolitical exposure (Macro): A meaningful revenue slice is tied to China and to global trade; tariffs or restrictions could hit both demand and cost.
- Leverage and interest cost (Financial): Total borrowings near $43bn after the Clario financing raise interest expense and constrain flexibility if cash flow softens.
- Integration and M&A execution (Operational): The growth model depends on repeatedly integrating large acquisitions; a misstep on Clario or a future deal could dilute returns.
- End-market cyclicality (Operational): Pharma and biotech capital-equipment spending is cyclical and can weaken faster than the recurring base can offset.
- Competitive intensity (Operational): Danaher, Agilent, Waters, Bruker and others compete aggressively on instrument performance and price in overlapping categories.
- Currency translation (Macro): A large international footprint means reported revenue and earnings are sensitive to a stronger US dollar.
11. Recent Developments
- 01 Jul 2026 — Dividend, forensics clearance and mRNA partnership. The board declared a quarterly dividend of $0.47; the RapidINTEL Plus DNA cartridge was approved for the FBI's national DNA index; and Thermo Fisher joined Arcturus Therapeutics to support Phase 3 development of an mRNA cystic-fibrosis therapy.
- 23 Apr 2026 — Q1 2026 results beat and guidance raised. Revenue rose 6% to $11.01bn with adjusted EPS of $5.44 and GAAP EPS of $4.43; management raised full-year revenue guidance to $47.3–$48.1bn and adjusted EPS to $24.64–$25.12, reflecting Clario.
- 24 Mar 2026 — Clario acquisition completed. Thermo Fisher closed the $8.875bn cash purchase of clinical-trial data firm Clario, expanding its clinical-development capabilities.
- 29 Jan 2026 — Q4 and full-year 2025 results. Full-year revenue grew 4% to $44.56bn with adjusted EPS up 5% to $22.87; Q4 revenue was $12.2bn and Q4 adjusted EPS $6.57.
- 29 Oct 2025 — Clario deal announced. The company agreed to acquire Clario for about $8.9bn in cash, plus performance-based payments.
12. Key Dates
- 23 Jul 2026 — Q2 2026 results before market open, with conference call at 8:30 a.m. ET
- 15 Oct 2026 — expected Q3 2026 results (provisional, based on prior-year cadence)
- 28 Jan 2027 — expected Q4 and full-year 2026 results (provisional)
For scheduled market-moving events and earnings, keep an eye on the ChartsView Economic Calendar, and discuss ideas on the Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 15 July 2026
Amgen Inc. (NASDAQ: AMGN) is one of the world's largest biotechnology companies, discovering, manufacturing and selling biologic medicines across general medicine, oncology, inflammation and rare disease. The investment debate in mid-2026 is finely balanced: sixteen brands are growing at double-digit rates and full-year guidance was raised in April, yet biosimilar erosion is accelerating across the legacy denosumab franchise (Prolia/XGEVA) and the market is waiting on pivotal Phase 3 obesity data for MariTide — the readout that could reset the company's growth profile — expected from the beginning of 2027. This research lays out the reported facts from primary filings so you can weigh the trade-offs yourself.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Amgen Inc. |
| Ticker / Exchange | AMGN / NASDAQ |
| Sector | Healthcare — Biotechnology |
| Headquarters | Thousand Oaks, California, USA |
| Founded | 1980 |
| CEO / Leadership | Robert A. Bradway (Chairman & Chief Executive Officer since 2012) |
| Employees | Approximately 31,500 in over 50 countries (about 13,000 outside the US), per FY2025 Form 10-K |
| Market cap | ~$192.7bn (~$356 per share, 14 July 2026) |
| Revenue (FY2025) | $36,751m total revenues ($35,148m product sales + $1,603m other revenues) |
| Net income (FY2025) | $7,711m GAAP; diluted GAAP EPS $14.23 (non-GAAP EPS $21.84) |
| Dividend | $2.52 per share quarterly for 2026 (+6% year-over-year; ~$10.08 annualised, ~2.8% yield) — 14+ consecutive years of dividend growth |
| Fiscal year end | 31 December |
2. Bull & Bear Case
Bull Case
- Broad-based growth engine: Sixteen brands delivered double-digit sales growth in Q1 2026 and seventeen products are annualising at more than $1bn; growth is spread across Repatha (+36% in FY2025), EVENITY (+34%), TEZSPIRE (+52%), BLINCYTO (+28%), UPLIZNA (+73%) and TAVNEOS (+62%), reducing single-product dependency.
- MariTide obesity optionality: Phase 2 data showed up to ~20% average weight loss at 52 weeks without plateau on monthly (or less frequent) dosing; the Phase 3 MARITIME programme (MARITIME-1, ~3,500 patients; MARITIME-2 in type-2 diabetes; MARITIME-Switch launched Q1 2026) reads out from the beginning of 2027 and could give Amgen a differentiated entry into the biggest market in pharma.
- Raised guidance with elite margins: After a Q1 2026 beat, management raised FY2026 guidance to $37.1–38.5bn revenue and $21.70–23.10 non-GAAP EPS; non-GAAP operating margin was 45% in Q1 2026 and 46.1% for FY2025, among the best in large-cap biopharma.
- Deleveraging plus growing income stream: Long-term debt has fallen from $63.2bn at YE2023 (post-Horizon) to $50.0bn at YE2025, while the dividend was raised 6% for 2026 ($2.52/quarter) — the balance sheet is steadily rebuilding capacity for the next pipeline investment cycle.
Bear Case
- Accelerating biosimilar erosion of the denosumab franchise: Prolia sales fell 10% year-over-year in Q4 2025 and XGEVA fell 20%, with management explicitly guiding to "accelerated sales erosion" in 2026 as multiple biosimilars launch globally — a ~$6.5bn annual franchise is now in decline.
- Legacy drag and pricing pressure: Enbrel, Otezla (a $400m impairment was taken in Q3 2025) and mature biosimilar-exposed brands offset growth elsewhere, while net selling prices fell 2–3% across the portfolio and US policy pressure (IRA price negotiation, potential tariffs) builds.
- Obesity race is crowded and unforgiving: MariTide arrives years behind Eli Lilly and Novo Nordisk, Phase 2 showed meaningful gastrointestinal tolerability challenges at initiation, and pivotal data are not due until 2027 — any stumble removes the main upside catalyst embedded in the shares.
- Near-term regulatory and sentiment overhangs: TAVNEOS faces a 29 July 2026 FDA deadline tied to its confirmatory-evidence requirements, and July 2026 saw analyst caution (Morgan Stanley target trimmed to $333; Bank of America reiterating a Sell with $312 target) with consensus modelling a ~8% EPS decline for Q2 2026.
3. Business Segments
Amgen operates as a single human-therapeutics business; the practical revenue split is by product. FY2025 total revenues were $36,751m — the largest contributors:
| Segment | % of revenue | What it is |
|---|---|---|
| Prolia (denosumab) | 12.0% ($4,414m) | Osteoporosis biologic; now facing global biosimilar competition with erosion accelerating in 2026 |
| Repatha (evolocumab) | 8.2% ($3,016m) | PCSK9 cholesterol-lowering injection; +36% in FY2025 on volume growth |
| EVENITY (romosozumab) | 5.7% ($2,100m) | Bone-building osteoporosis biologic; +34% in FY2025 |
| TEPEZZA (teprotumumab) | 5.2% ($1,903m) | Thyroid eye disease therapy acquired with Horizon Therapeutics (2023) |
| BLINCYTO (blinatumomab) | 4.2% ($1,559m) | Bispecific T-cell engager for acute lymphoblastic leukaemia; +28% in FY2025 |
| All other products & other revenues | ~64.7% (~$23,759m) | Includes Enbrel, Otezla, XGEVA, KYPROLIS, TEZSPIRE, Nplate, KRYSTEXXA, UPLIZNA, TAVNEOS, IMDELLTRA, biosimilars (PAVBLU, WEZLANA, AMGEVITA and others) and royalty/collaboration income |
4. Business Model & Moat
How it makes money. Amgen discovers, develops, manufactures and sells biologic medicines, largely reimbursed by governments and private insurers. Product sales were $35.1bn of FY2025's $36.8bn total revenues, with the remainder from collaborations and royalties. The portfolio spans four therapeutic areas — general medicine (Repatha, EVENITY, Prolia), rare disease (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS — largely from the $27.8bn Horizon Therapeutics acquisition completed in 2023), inflammation (Enbrel, Otezla, TEZSPIRE, AMGEVITA) and oncology (BLINCYTO, IMDELLTRA, KYPROLIS, Vectibix, biosimilars).
The moat. Biologics are hard to copy: complex manufacturing at scale, decades of process know-how, and an installed base of prescriber and payer relationships create high barriers. Amgen is also one of the few originators to run a large biosimilars business of its own (PAVBLU, WEZLANA, BEKEMV), turning the biosimilar threat into a revenue line — PAVBLU alone generated $700m in its first full year (FY2025). Patents remain the core protection, which is why the pipeline (MariTide, rocatinlimab, bemarituzumab, olpasiran) matters so much.
Cash generation and capital allocation. FY2025 free cash flow was $8.1bn (operating cash flow $9,958m less capital expenditures $1,858m), funding a growing dividend (~$5.2bn/year), debt paydown (long-term debt down $6.5bn in 2025) and R&D of $7.3bn (+22% year-over-year). No shares were repurchased in 2025 as deleveraging took priority.
5. Financial Health
All figures from Amgen earnings press releases and SEC filings (10-K/8-K, XBRL). Dividend/share is the total declared for each calendar year's quarterly payments.
| Fiscal Year | Revenue ($m) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| FY2021 | $25,979m | +2.2% | $10.28 | $17.10 | $7.04 | $33,222m |
| FY2022 | $26,323m | +1.3% | $12.11 | $17.69 | $7.76 | $37,354m |
| FY2023 | $28,190m | +7.1% | $12.49 | $18.65 | $8.52 | $63,170m |
| FY2024 | $33,424m | +18.6% | $7.56 | $19.84 | $9.00 | $56,549m |
| FY2025 | $36,751m | +10.0% | $14.23 | $21.84 | $9.52 | $50,005m |
The FY2023 jump in long-term debt funded the $27.8bn Horizon Therapeutics acquisition (closed October 2023), which also drove FY2024's revenue surge and depressed FY2024 GAAP EPS ($7.56) through acquisition-related amortisation and charges. FY2025 GAAP EPS of $14.23 was flattered by $2,651m of net other income (largely gains on equity investments) and includes a $400m Otezla intangible impairment; adjusted (non-GAAP) EPS of $21.84 grew 10%. FY2025 operating cash flow was $9,958m, capital expenditures $1,858m and depreciation & amortisation $5,167m.
| Quarter / Half | Revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 2026 | $8,618m | $5.15 | $3.34 |
| Q4 2025 | $9,866m | $5.29 | $2.45 |
| Q3 2025 | $9,558m* | $5.64 | $5.93 |
| Q2 2025 | $9,178m* | $6.02 | $2.65 |
| FY2025 total | $36,751m | $21.84 | $14.23 |
*Q2 2025 revenue is product sales of $8,770m plus other revenues of $408m as reported; Q3 2025 revenue derived arithmetically from full-year and other reported quarters (press releases round to "$9.6bn, +12%"). Q3 2025 GAAP EPS ($5.93) exceeded non-GAAP ($5.64) because of large net gains on equity investments recorded in GAAP other income. Q1 2026 (reported 30 April 2026): revenue +6%, non-GAAP EPS +5%, and FY2026 guidance raised to $37.1–38.5bn revenue, GAAP EPS $15.62–17.10 and non-GAAP EPS $21.70–23.10.
6. Valuation Metrics
Raw metrics, July 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$192.7bn (~$356.57/share on 14 Jul 2026; ~540m shares outstanding) |
| Trailing P/E (GAAP) | ~24.8x (TTM GAAP EPS $14.37 = Q2 2025 $2.65 + Q3 2025 $5.93 + Q4 2025 $2.45 + Q1 2026 $3.34); note GAAP EPS over this period is materially affected by swings in unrealised equity-investment gains/losses |
| P/E (forward) | ~15.9x on the midpoint of raised FY2026 non-GAAP EPS guidance of $21.70–23.10 (~$22.40); ~21.8x on the midpoint of GAAP EPS guidance of $15.62–17.10 |
| P/S (TTM) | ~5.2x (market cap ~$192.7bn / TTM revenue ~$37.2bn) |
| Enterprise value | ~$238bn (market cap ~$192.7bn + total debt $57.3bn ($5,437m current portion + $51,886m long-term) − cash and cash equivalents $12.0bn, per 31 Mar 2026 balance sheet) |
| EV/EBITDA (TTM) | ~16.7x on FY2025 GAAP EBITDA of ~$14.2bn (operating income $9,080m + D&A $5,167m); GAAP operating income carries heavy acquisition-related amortisation and the $400m Otezla impairment — on FY2025 non-GAAP operating income ($16.2bn) plus D&A the multiple is materially lower |
| P/FCF | ~23.8x (market cap ~$192.7bn / FY2025 free cash flow ~$8.1bn; FCF = operating cash flow $9,958m − capital expenditures $1,858m per FY2025 cash flow statement) |
| 52-week high | $391.29 (all-time closing high $385.25 on 27 Feb 2026) |
| 52-week low | $269.77 |
| Short interest (% of float) | 2.37% (12.74m shares per the February 2026 settlement report; down from 2.79% in January 2026) |
| Days to cover | 4.31 (February 2026 report) |
7. What Are They Building
An obesity franchise. MariTide (maridebart cafraglutide), a monthly-or-less-frequent GIPR/GLP-1 injectable, showed up to ~20% average weight loss at 52 weeks in Phase 2 without a plateau. The Phase 3 MARITIME programme spans obesity (MARITIME-1, ~3,500 participants), obesity with type-2 diabetes (MARITIME-2), a switch study from weekly GLP-1s (MARITIME-Switch, started Q1 2026) and cardiovascular-outcomes work, with primary readouts guided from the beginning of 2027. Commercial leadership has publicly positioned MariTide as potentially "the best monthly or less frequently dosed agent" in obesity.
The next wave of Phase 3 molecules. Beyond MariTide, late-stage assets include rocatinlimab (atopic dermatitis), bemarituzumab (gastric cancer), olpasiran (Lp(a) reduction for cardiovascular risk) and expanding indications for IMDELLTRA (small-cell lung cancer) and UPLIZNA (IgG4-related disease, generalised myasthenia gravis). R&D spend rose 22% in FY2025 to $7.3bn to fund this wave.
Scale manufacturing and biosimilars. Amgen is investing in US manufacturing capacity (including new plants in Ohio and North Carolina) and building out its biosimilars unit — PAVBLU (aflibercept biosimilar) delivered $700m in its first full year, WEZLANA (ustekinumab) $273m — providing a counter-cyclical revenue stream as its own legacy biologics face biosimilar competition.
8. Peer Comparison
| Peer | Market cap (July 2026) | Key 2025 metric |
|---|---|---|
| Eli Lilly (LLY) | ~$1,150bn | Obesity/diabetes leader (Zepbound, Mounjaro) — the incumbent MariTide must challenge |
| Johnson & Johnson (JNJ) | ~$621bn | Diversified pharma & medtech; largest US healthcare company by revenue |
| AbbVie (ABBV) | ~$445bn | Immunology peer managing its own patent cliff (Humira) via Skyrizi/Rinvoq growth |
| Gilead Sciences (GILD) | ~$158bn | Closest large-cap biotech comparable by size; HIV-led portfolio |
Peer market caps as reported by public market-data aggregators in early July 2026; figures move daily and should be re-checked at the time of reading.
9. Insider Activity
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Robert A. Bradway (Chairman & CEO) | 16 Mar 2026 | Tax withholding (F-code) | 21,294 | $366.21 | ~$7.8m | Shares withheld to cover tax on vesting equity — not an open-market sale |
| Robert A. Bradway (Chairman & CEO) | 05 May 2026 | Grant | 12,136 RSUs + 79,176 options | $329.59 (option strike) | — | Annual Equity Incentive Plan award, vesting 25%/year from May 2027 |
| Robert A. Bradway (Chairman & CEO) | 06 May 2026 | Tax withholding (F-code) | 1,702 | $329.59 | ~$0.6m | Shares withheld for tax — not an open-market sale |
2026 Form 4 filings show routine equity awards and tax-withholding dispositions; there have been no material insider open-market purchases or sales reported this year. Chairman & CEO Robert A. Bradway directly holds around 507,000 shares after these transactions.
10. Key Risks
- Biosimilar erosion: Prolia and XGEVA (denosumab, ~$6.5bn combined FY2025 sales) face multiple global biosimilar launches with management guiding to accelerated erosion through 2026; Enbrel and Otezla continue to decline, and RAVICTI faces generic competition.
- Pipeline/binary-event risk: The MARITIME Phase 3 obesity readouts (from early 2027) are the single biggest swing factor for the shares; Phase 2 gastrointestinal tolerability issues and formidable competition from Eli Lilly and Novo Nordisk make outcomes uncertain.
- Regulatory risk: TAVNEOS faces a 29 July 2026 FDA deadline linked to confirmatory-evidence requirements; more broadly, IRA Medicare price negotiation, potential US pharmaceutical tariffs and drug-pricing policy could compress US net prices (already down 2–3% portfolio-wide).
- Balance-sheet risk: Total debt was still $57.3bn at 31 March 2026 against $12.0bn of cash; while deleveraging is on track, higher-for-longer rates raise refinancing costs and constrain large-scale M&A.
- Concentration in the US market: Roughly three-quarters of product sales are US-derived, exposing Amgen to a single payer/policy environment.
- Litigation and tax risk: Amgen carries long-running IRS transfer-pricing disputes (multi-billion-dollar claimed deficiencies for 2010–2015) and routine patent litigation, either of which could produce material one-off charges.
11. Recent Developments
- 30 Apr 2026 — Q1 2026 beat and raised guidance. Total revenues rose 6% to $8.62bn; non-GAAP EPS of $5.15 beat consensus (~$4.77) and GAAP EPS rose 4% to $3.34 as GAAP operating margin expanded 17.4 points to 32.4%. FY2026 guidance was raised to $37.1–38.5bn revenue and $21.70–23.10 non-GAAP EPS; sixteen brands grew double-digit and free cash flow was $1.5bn.
- 03 Feb 2026 — FY2025 results: double-digit top and bottom-line growth. FY2025 total revenues rose 10% to $36.8bn (13% volume growth), non-GAAP EPS rose 10% to $21.84 and free cash flow was $8.1bn. Repatha (+36%), EVENITY (+34%) and TEZSPIRE (+52%) led growth while management flagged accelerated 2026 erosion for Prolia/XGEVA from biosimilars.
- 23 Jun 2025 — Full MariTide Phase 2 data at ADA. Amgen presented 52-week Phase 2 results showing up to ~20% average weight loss in obesity (2.6% placebo) and ~17% with type-2 diabetes, with weight loss not plateaued; the Phase 3 MARITIME programme is enrolling with primary readouts guided from the beginning of 2027, including the MARITIME-Switch study launched in Q1 2026.
- 14 Jul 2026 — Analyst caution ahead of Q2 results. The shares closed at $355.25 (−1.44% on the day); Morgan Stanley trimmed its target to $333 (Equal Weight) and Bank of America reiterated a Sell with a $312 target, with Q2 2026 consensus modelling EPS of ~$5.55 (−8% year-over-year) on revenue of ~$9.45bn. ChartsView does not use analyst opinions in its own assessment; these are noted purely as market-moving events.
12. Key Dates & What to Watch
- 29 Jul 2026 — FDA deadline concerning TAVNEOS confirmatory-evidence requirements — watch for a resolution or withdrawal decision
- 04 Aug 2026 — Q2 2026 results and earnings call (1:30pm PDT, per Amgen's investor-relations events calendar) — watch Prolia/XGEVA erosion pace versus growth-brand momentum
- Expected Sep 2026 — next quarterly dividend payment ($2.52 per share run-rate)
- Expected Oct 2026 — Q3 2026 results (early November in prior years; date to be confirmed by the company)
- Expected Jan 2027 — MARITIME-1 and MARITIME-2 Phase 3 primary readouts window opens ("beginning of 2027" per company guidance) — the pivotal catalyst for the obesity thesis
Track AMGN price action on our Live Charts, upcoming macro catalysts on the Economic Calendar, and join the discussion in the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 11 July 2026
Vertex Pharmaceuticals is the world leader in cystic fibrosis (CF), where its CFTR-modulator medicines dominate a franchise that generated $12.0 billion in 2025 revenue. After decades as effectively a single-disease company, Vertex is now diversifying: it has launched a CRISPR gene-editing therapy (CASGEVY), the first new class of non-opioid acute-pain medicine in decades (JOURNAVX), a next-generation once-daily CF regimen (ALYFTREK), and in July 2026 agreed its largest-ever acquisition — endocrinology specialist Crinetics — for roughly $10 billion. This report examines the numbers, the pipeline and the risks behind that transition. See also our Live Charts and Economic Calendar.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | Vertex Pharmaceuticals Incorporated |
| Ticker / Exchange | VRTX / NASDAQ |
| Sector | Healthcare — Biotechnology |
| CEO | Dr Reshma Kewalramani (President & CEO since April 2020) |
| Headquarters | Boston, Massachusetts, USA |
| Founded | 1989 |
| Employees | ~6,400 (as of 31 December 2025) |
| Market cap | ~$125bn (10 July 2026) |
| Revenue (FY2025) | $12.00bn (+8.9% YoY) |
| Net income (FY2025, GAAP) | $3.95bn |
| GAAP EPS / Non-GAAP EPS (FY2025) | $15.32 / $18.40 |
| Dividend | None — Vertex pays no dividend |
2. Bull & Bear Case
Bull Case
- Unrivalled cystic-fibrosis franchise: Vertex is the only company with approved medicines that treat the underlying cause of CF, giving it durable pricing power, high margins and a patient base it can expand to younger ages and more mutations.
- Real diversification is finally arriving: CASGEVY (gene editing), JOURNAVX (non-opioid pain) and the next-generation ALYFTREK regimen all contributed to 2026 growth, and povetacicept in IgA nephropathy is near commercialisation — reducing single-disease dependency.
- Fortress balance sheet: the company is debt-free with $12.3 billion of cash and investments and generated roughly $3.2 billion of free cash flow in 2025, funding both R&D and large acquisitions from internal resources.
- Large addressable expansion: the pending ~$10 billion Crinetics acquisition adds a commercialised acromegaly drug and a Phase 3 pipeline with a stated ~$5 billion peak-sales opportunity in endocrinology.
- Consistent top-line growth: revenue has compounded from $7.6 billion in 2021 to $12.0 billion in 2025, and management reiterated 2026 guidance of $12.95–13.1 billion (8–9% growth).
Bear Case
- Extreme CF concentration: roughly 98% of revenue still comes from cystic-fibrosis medicines, so any efficacy, safety, patent or reimbursement shock to that franchise would be severe.
- Rich valuation leaves little slack: the stock trades at roughly 29x trailing GAAP earnings and ~39x free cash flow, pricing in successful execution of the diversification story.
- Acquisition and integration risk: the $10 billion Crinetics deal follows the 2024 Alpine Immune purchase, whose in-process R&D charge pushed Vertex to a full-year GAAP loss that year — large deals can distort earnings and strain focus.
- New-launch uptake is unproven at scale: JOURNAVX and CASGEVY are early in their commercial lives and face reimbursement, access and manufacturing hurdles before they move the needle on a $12 billion revenue base.
- Drug-pricing and policy headwinds: US Medicare price negotiation and broader pricing pressure could weigh on high-priced specialty medicines over time.
3. Business Segments
Vertex reports as a single product-revenue business, but its revenue can be viewed by therapeutic area. The cystic-fibrosis franchise remains overwhelmingly dominant, with the newer launches still small but growing quickly. The split below is approximate, based on FY2025 disclosures.
| Segment | % of revenue | What it is |
|---|---|---|
| Cystic Fibrosis | ~98% | CFTR-modulator medicines — TRIKAFTA/KAFTRIO (the dominant product), the next-generation once-daily ALYFTREK, plus older CF therapies. Treats the underlying cause of the disease. |
| CASGEVY (cell & gene therapy) | ~1% | First approved CRISPR gene-editing therapy, for sickle cell disease and transfusion-dependent beta thalassemia; partnered with CRISPR Therapeutics. |
| JOURNAVX & other (acute pain) | ~1% | First-in-class non-opioid NaV1.8 pain medicine launched in 2025; more than 1 million prescriptions filled to date. |
4. Business Model
Vertex is a fully integrated biopharmaceutical company: it discovers, develops, manufactures and commercialises its own medicines rather than relying on partners, which lets it capture the full economics of each drug.
How it makes money. Revenue is almost entirely product sales of prescription medicines, sold to specialty pharmacies, distributors and health systems in the US and, outside the US, largely through reimbursement agreements with national health authorities. Cystic fibrosis is a chronic condition, so patients typically remain on therapy for life, producing highly recurring, high-margin revenue.
Unit economics and moat. Gross margins are very high because the marginal cost of a small-molecule pill is low relative to price. Vertex's moat rests on being the only firm to have cracked CFTR modulation, protected by patents, manufacturing know-how and deep relationships with the CF patient community. It reinvests heavily — R&D runs into the billions annually — to extend the CF franchise and to build the non-CF pipeline that underpins the long-term growth story.
Capital allocation. With no dividend and no debt, Vertex deploys its cash into R&D, share repurchases and acquisitions (Alpine Immune in 2024, Crinetics announced in 2026).
5. Financial Health
Vertex has grown revenue every year while remaining debt-free. The one GAAP anomaly is 2024, when a large acquired in-process R&D charge from the Alpine Immune acquisition pushed the company to a full-year net loss; non-GAAP earnings that year were only marginally positive for the same reason. All figures below are from Vertex's earnings press releases and SEC filings.
| Year | Revenue | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE) |
|---|---|---|---|---|---|---|
| 2021 | $7.57bn | — | $9.01 | $9.67 | Nil | $0m |
| 2022 | $8.93bn | +17.9% | $12.82 | $14.88 | Nil | $0m |
| 2023 | $9.87bn | +10.5% | $13.89 | $15.23 | Nil | $0m |
| 2024 | $11.02bn | +11.7% | $(2.08) | $0.42 | Nil | $0m |
| 2025 | $12.00bn | +8.9% | $15.32 | $18.40 | Nil | $0m |
Vertex carries no long-term borrowings; it is debt-free and held $12.3 billion in cash and marketable securities at 31 December 2025. Adjusted (non-GAAP) EPS excludes acquired IPR&D, amortisation and other items; the 2024 figures reflect the ~$4.4 billion Alpine Immune in-process R&D charge.
| Quarter | Revenue | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 2026 | $2.99bn | $4.47 | $4.02 |
| Q4 2025 | $3.19bn | $5.03 | $4.65 |
| Q3 2025 | $3.08bn | $4.80 | $4.20 |
| Q2 2025 | $2.96bn | $4.52 | $3.99 |
| FY2025 total | $12.00bn | $18.40 | $15.32 |
6. Valuation
Raw metrics, July 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$125bn (~256m shares × $485.69, 10 Jul 2026) |
| Enterprise value | ~$113bn (market cap $125bn − net cash $12.3bn; company is debt-free) |
| Trailing P/E (GAAP) | ~29x (price $485.69 / TTM GAAP EPS $16.85) |
| P/E (forward) | n/a — Vertex does not issue EPS guidance |
| P/S (TTM) | ~10x (market cap $125bn / TTM revenue ~$12.2bn) |
| P/FCF | ~39x (market cap $125bn / FY2025 FCF ~$3.19bn; FCF = operating CF $3.63bn − capex $0.44bn) |
| EV/EBITDA (TTM) | ~26x (EV $113bn / FY2025 EBITDA ~$4.38bn; operating income $4.17bn + D&A $0.21bn) |
| 52-week high | $533.67 |
| 52-week low | $362.50 |
| Short interest (% of float) | ~2.0% |
| Days to cover | ~3 |
7. What Are They Building
Vertex's strategy is to leverage its cystic-fibrosis cash engine to build a multi-franchise specialty pharma. The near-term pipeline and launches include: ALYFTREK, the next-generation once-daily CF regimen now expanding to younger age groups and new geographies; CASGEVY, the CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, which in July 2026 gained a US FDA label extension to patients as young as two; and JOURNAVX (suzetrigine), the first-in-class non-opioid NaV1.8 acute-pain medicine, which surpassed one million filled prescriptions since its 2025 launch.
Beyond these, Vertex is preparing to commercialise povetacicept in IgA nephropathy, is advancing zimislecel, a stem-cell-derived islet therapy aimed at curing type 1 diabetes, and is developing programmes in kidney disease (APOL1-mediated) and pain. The pending acquisition of Crinetics would add PALSONIFY (paltusotine) for acromegaly and atumelnant (Phase 3 for congenital adrenal hyperplasia), opening an entirely new endocrinology franchise with a stated ~$5 billion peak-sales opportunity.
8. Competitive Landscape
Vertex has no direct competitor in cystic-fibrosis CFTR modulation, so its rivals are best seen across the therapeutic areas it is entering — gene editing, non-opioid pain and, via Crinetics, endocrinology — and among large-cap biopharma peers competing for capital and pipeline assets.
| Peer | Market cap (Jul 2026) | Key 2025 metric |
|---|---|---|
| CRISPR Therapeutics (CRSP) | ~$6bn | Co-developer of CASGEVY; pre-profit gene-editing biotech |
| Regeneron (REGN) | ~$60bn | FY2025 revenue ~$14bn; large-cap biotech peer |
| Gilead Sciences (GILD) | ~$140bn | FY2025 revenue ~$29bn; established specialty pharma |
| Amgen (AMGN) | ~$160bn | FY2025 revenue ~$34bn; diversified biologics leader |
Peer market caps are approximate and as of July 2026.
9. Leadership & Ownership
Vertex is led by President & CEO Dr Reshma Kewalramani, a physician-scientist who took the top job in April 2020 — the first woman to run a large-cap public biotech. Chairman and founder-era figure Jeffrey Leiden remains Executive Chairman of the board. Recent insider activity has been routine: equity awards vesting and tax-related dispositions rather than open-market buying or selling of conviction.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Reshma Kewalramani (CEO) | 20 Feb 2026 | RSU grant (award) | 16,326 | $0.00 | $0 | Equity compensation |
| Reshma Kewalramani (CEO) | 20 Feb 2026 | Disposition (tax withholding) | 6,554 | $483.75 | ~$3.2m | Tax withholding on vesting |
10. Key Risks
- Concentration (Operational): ~98% of revenue depends on the cystic-fibrosis franchise; a competitive, clinical or reimbursement shock there would be material.
- Patent and competition (Legal/Operational): CF-franchise patents will eventually expire and rivals continue to research CFTR modulators and other approaches.
- Pipeline execution (Operational): clinical-trial failures or slow uptake of CASGEVY, JOURNAVX, povetacicept or zimislecel could undermine the diversification thesis.
- Acquisition integration (Financial): the ~$10 billion Crinetics deal and prior Alpine Immune purchase carry integration, dilution and impairment risk, and large IPR&D charges can distort GAAP earnings.
- Drug pricing and policy (Regulatory): US Medicare price negotiation and global pricing pressure could erode the economics of high-priced specialty medicines.
- Valuation (Market): at ~29x earnings and ~39x free cash flow, the shares leave limited room for disappointment.
11. Recent Developments
- 06 Jul 2026 — Vertex agrees to acquire Crinetics for ~$10 billion. The all-cash deal at $85.00 per Crinetics share (~$8.8 billion net of cash) adds commercialised and Phase 3 endocrinology assets with a stated ~$5 billion peak-sales opportunity; closing is expected in Q3 2026. It is Vertex's largest-ever acquisition.
- 01 Jul 2026 — FDA expands CASGEVY to children aged two and older. The approval makes CASGEVY the first gene-based therapy cleared for patients as young as two for both sickle cell disease and transfusion-dependent beta thalassemia.
- 04 May 2026 — Q1 2026 results. Revenue rose 8% to $2.99 billion with GAAP EPS of $4.02 and non-GAAP EPS of $4.47; full-year 2026 guidance of $12.95–13.1 billion was reiterated. CASGEVY contributed $43 million and JOURNAVX $29 million in the quarter.
- 11 Feb 2026 — Q4 and full-year 2025 results. Full-year revenue reached $12.0 billion (+9%), with GAAP EPS of $15.32 and non-GAAP EPS of $18.40; cash and investments stood at $12.3 billion.
12. Key Dates
- 03 Aug 2026 — Q2 2026 financial results (after market close)
- Expected Q3 2026 — anticipated closing of the Crinetics acquisition
- Expected Nov 2026 — Q3 2026 financial results
For more tools, see the ChartsView Live Charts, Economic Calendar and community Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.